<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12250743</article-id><article-id pub-id-type="pmcid-ver">PMC12250743.1</article-id><article-id pub-id-type="pmcaid">12250743</article-id><article-id pub-id-type="pmcaiid">12250743</article-id><article-id pub-id-type="pmid">40649373</article-id><article-id pub-id-type="doi">10.3390/molecules30132858</article-id><article-id pub-id-type="publisher-id">molecules-30-02858</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Foeniculum vulgare</italic> Mill. Mitigates Scopolamine-Induced Cognitive Deficits via Antioxidant and Neuroprotective Mechanisms in Zebrafish</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3103-9728</contrib-id><name name-style="western"><surname>Brinza</surname><given-names initials="I">Ion</given-names></name><xref rid="af1-molecules-30-02858" ref-type="aff">1</xref><xref rid="fn1-molecules-30-02858" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2602-4882</contrib-id><name name-style="western"><surname>Boiangiu</surname><given-names initials="RS">Razvan Stefan</given-names></name><xref rid="af2-molecules-30-02858" ref-type="aff">2</xref><xref rid="fn1-molecules-30-02858" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Todirascu-Ciornea</surname><given-names initials="E">Elena</given-names></name><xref rid="af2-molecules-30-02858" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6981-4174</contrib-id><name name-style="western"><surname>Hritcu</surname><given-names initials="L">Lucian</given-names></name><xref rid="af2-molecules-30-02858" ref-type="aff">2</xref><xref rid="c1-molecules-30-02858" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dumitru</surname><given-names initials="G">Gabriela</given-names></name><xref rid="af2-molecules-30-02858" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Prokai-Tatrai</surname><given-names initials="K">Katalin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-02858"><label>1</label>Faculty of Sciences, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania; <email>ion.brinza@ulbsibiu.ro</email></aff><aff id="af2-molecules-30-02858"><label>2</label>Department of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, 700506 Iasi, Romania; <email>razvan.boiangiu@uaic.ro</email> (R.S.B.); <email>ciornea@uaic.ro</email> (E.T.-C.); <email>gabriela.dumitru@uaic.ro</email> (G.D.)</aff><author-notes><corresp id="c1-molecules-30-02858"><label>*</label>Correspondence: <email>hritcu@uaic.ro</email>; Tel.: +40-232-201-666</corresp><fn id="fn1-molecules-30-02858"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>30</volume><issue>13</issue><issue-id pub-id-type="pmc-issue-id">492765</issue-id><elocation-id>2858</elocation-id><history><date date-type="received"><day>18</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-14 13:25:33.110"><day>14</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-02858.pdf"/><abstract><p><italic toggle="yes">Foeniculum vulgare</italic> Mill. (Apiaceae) is an aromatic medicinal plant known for its anti-inflammatory, antispasmodic, antiseptic, carminative, diuretic, and analgesic properties. This study aimed to investigate the effects of <italic toggle="yes">F. vulgare</italic> essential oil (FVEO; 25, 150, and 300 &#956;L/L) on the cognitive performance and brain oxidative stress in a scopolamine (SCOP; 100 &#956;M)-induced zebrafish model of cognitive impairment. Additionally, the pharmacokinetic properties and bioactivity profiles of the main FVEO constituents were predicted to be used in silico tools, including SwissADME, pkCSM, PASS online, and ADMETlab 2.0. Behavioral assays, novel tank diving test (NTT), Y-maze, and novel object recognition (NOR) test, were used to evaluate anxiety-like behavior, spatial memory, and recognition memory, respectively. Biochemical assessments of acetylcholinesterase (AChE) activity and oxidative stress biomarkers were also conducted. The results demonstrated that FVEO significantly improved cognitive performance in SCOP-treated zebrafish, normalized AChE activity, and reduced oxidative stress in the brain. These findings suggest the therapeutic potential of FVEO in ameliorating memory impairment and oxidative damage associated with neurodegenerative disorders such as Alzheimer&#8217;s disease (AD).</p></abstract><kwd-group><kwd><italic toggle="yes">Foeniculum vulgare</italic> essential oil</kwd><kwd>oxidative stress</kwd><kwd>acetylcholinesterase</kwd><kwd>in silico analysis</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>neuroprotection</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI</funding-source><award-id>PN-III-P4-PCE-2021-1692</award-id></award-group><funding-statement>I.B., R.S.B. and L.H. were supported by a grant by the Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI, project number PN-III-P4-PCE-2021-1692, within PNCDI III.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-02858"><title>1. Introduction</title><p>Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disease that is the most common form of dementia worldwide [<xref rid="B1-molecules-30-02858" ref-type="bibr">1</xref>]. It is primarily characterized by the accumulation of amyloid-&#946; plaques, hyperphosphorylated tau tangles, oxidative stress, and neuroinflammation. These pathological hallmarks often co-occur with cholinergic dysfunction, forming a complex network of interacting mechanisms that exacerbate disease progression [<xref rid="B2-molecules-30-02858" ref-type="bibr">2</xref>,<xref rid="B3-molecules-30-02858" ref-type="bibr">3</xref>]. AD is a complex and multifactorial neurodegenerative disorder, characterized by cholinergic deficits, &#946;-amyloid peptide aggregation, accumulation of hyperphosphorylated tau proteins, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation. Disruption of redox homeostasis and microglial activation contribute to synaptic loss and neuronal degeneration, while transcriptional dysregulation of key regulatory factors such as nuclear factor erythroid 2-related factor 2 (Nrf2), cAMP response element-binding protein (CREB), and brain-derived neurotrophic factor (BDNF) impairs neuronal resilience and synaptic plasticity [<xref rid="B4-molecules-30-02858" ref-type="bibr">4</xref>,<xref rid="B5-molecules-30-02858" ref-type="bibr">5</xref>,<xref rid="B6-molecules-30-02858" ref-type="bibr">6</xref>].</p><p>The cholinergic system, particularly acetylcholine (ACh), plays a central role in the pathophysiology of AD and remains a critical target for therapeutic intervention [<xref rid="B7-molecules-30-02858" ref-type="bibr">7</xref>,<xref rid="B8-molecules-30-02858" ref-type="bibr">8</xref>,<xref rid="B9-molecules-30-02858" ref-type="bibr">9</xref>]. In AD, cholinergic atrophy and cognitive decline are closely linked, and dysregulation of this system contributes to further neurodegenerative changes, including abnormal tau phosphorylation and enhanced neuroinflammatory responses [<xref rid="B7-molecules-30-02858" ref-type="bibr">7</xref>]. Current therapeutic strategies for AD primarily aim to restore cholinergic transmission and reduce oxidative stress. Clinically approved drugs such as cholinesterase inhibitors (AChEIs) and glutamate receptor antagonists have shown modest efficacy in improving cognitive symptoms [<xref rid="B8-molecules-30-02858" ref-type="bibr">8</xref>]. AChEIs increase synaptic ACh levels and thereby enhance neuronal function. Several classes of AChEIs have been developed, including synthetic analogs, hybrid compounds, and naturally derived inhibitors [<xref rid="B9-molecules-30-02858" ref-type="bibr">9</xref>]. Widely used agents such as donepezil, rivastigmine, and galantamine have demonstrated moderate success in improving cognition, behavior, and activities of daily living in patients with mild to moderate AD [<xref rid="B10-molecules-30-02858" ref-type="bibr">10</xref>]. However, these drugs are often associated with adverse effects, including gastrointestinal disturbances (nausea, vomiting, diarrhea) and cardiovascular complications such as bradycardia [<xref rid="B11-molecules-30-02858" ref-type="bibr">11</xref>]. Consequently, there is a pressing need to identify new therapeutic candidates with improved efficacy and safety profiles.</p><p>Scopolamine (SCOP), a muscarinic receptor antagonist, is frequently employed in experimental models to induce cognitive deficits resembling those observed in AD. SCOP administration leads to cholinergic dysfunction, amyloid-&#946; accumulation, tau hyperphosphorylation, and increased oxidative stress, key features implicated in AD pathology [<xref rid="B12-molecules-30-02858" ref-type="bibr">12</xref>,<xref rid="B13-molecules-30-02858" ref-type="bibr">13</xref>,<xref rid="B14-molecules-30-02858" ref-type="bibr">14</xref>,<xref rid="B15-molecules-30-02858" ref-type="bibr">15</xref>]. Although SCOP-based models are limited in their ability to fully replicate the human disease, they remain valuable tools for screening cognitive enhancers and neuroprotective agents.</p><p><italic toggle="yes">Foeniculum vulgare</italic> Mill. (Apiaceae), commonly known as fennel, has been traditionally used for its therapeutic properties, including anti-inflammatory, antioxidant, antispasmodic, diuretic, and analgesic effects. While direct evidence linking fennel to dementia is limited, its bioactive compounds suggest potential neuroprotective effects [<xref rid="B16-molecules-30-02858" ref-type="bibr">16</xref>,<xref rid="B17-molecules-30-02858" ref-type="bibr">17</xref>]. Notably, fennel has demonstrated efficacy in promoting nerve regeneration and functional recovery following peripheral nerve injury, indicating its potential role in neural health [<xref rid="B18-molecules-30-02858" ref-type="bibr">18</xref>]. The plant contains a range of pharmacologically active constituents such as anethole, fenchone, limonene, estragole, and <italic toggle="yes">p</italic>-coumaric acid, which exhibit antioxidant, anti-inflammatory, carminative, diuretic, and other beneficial properties [<xref rid="B19-molecules-30-02858" ref-type="bibr">19</xref>,<xref rid="B20-molecules-30-02858" ref-type="bibr">20</xref>]. Additionally, fennel seeds are rich in flavonoids, linalool, and fatty acids (e.g., palmitic and oleic acids), which contribute to their anti-inflammatory activity [<xref rid="B21-molecules-30-02858" ref-type="bibr">21</xref>]. Even the less-utilized parts of the plant, such as stems and leaves, contain phenolic acids and glycosylated flavonoids capable of inhibiting COX-2, further underscoring their therapeutic potential [<xref rid="B17-molecules-30-02858" ref-type="bibr">17</xref>].</p><p>The present study aimed to investigate the potential neuroprotective effects of <italic toggle="yes">F. vulgare</italic> essential oil (FVEO) in a SCOP-induced zebrafish model of cognitive impairment. Specifically, we evaluated the effects of FVEO on anxiety-like behavior, cognitive performance, AChE activity, and oxidative stress markers. Furthermore, the pharmacokinetic and toxicological properties of major FVEO constituents were predicted using integrated in silico approaches.</p></sec><sec sec-type="results" id="sec2-molecules-30-02858"><title>2. Results and Discussions</title><sec id="sec2dot1-molecules-30-02858"><title>2.1. Pharmacokinetic Profiles of Scopolamine, Galantamine, Trans-Anethole, Camphor, Trans-Sabinene Hydrate, (+)-Carvone, and &#946;-Pinene</title><p>Free online platforms such as SwissADME [<xref rid="B22-molecules-30-02858" ref-type="bibr">22</xref>], pKCSM [<xref rid="B23-molecules-30-02858" ref-type="bibr">23</xref>] and ADMETlab 2.0 [<xref rid="B24-molecules-30-02858" ref-type="bibr">24</xref>] were employed for the theoretical assessment of ADMET and pharmacokinetic properties of SCOP, galantamine (GAL), and the major bioactive constituents identified in FVEO from our previous study [<xref rid="B25-molecules-30-02858" ref-type="bibr">25</xref>]: <italic toggle="yes">trans</italic>-anethole (58.1%), camphor (21.3%), <italic toggle="yes">trans</italic>-sabinene hydrate (3.1%), (+)-carvone (7.8%), and <italic toggle="yes">&#946;</italic>-pinene (2.6%). Physicochemical parameters, including molecular weight, number of heavy atoms, number of aromatic heavy atoms, octanol-water partition coefficient (LogP), fraction of sp<sup>3</sup>-hybridized carbon atoms (Fraction Csp<sup>3</sup>), number of rotatable bonds, hydrogen bond acceptors and donors, molar refractivity, surface area, and topological polar surface area (TPSA) were analyzed (<xref rid="molecules-30-02858-t001" ref-type="table">Table 1</xref>) to characterize these compounds comprehensively.</p><p>Molecular weight impacts absorption, distribution, and elimination; the number of heavy atoms and aromatic heavy atoms reflects molecular complexity and ring structure. LogP is indicative of lipophilicity and affects solubility and membrane permeability. Fraction Csp<sup>3</sup> denotes the saturation level and three-dimensionality of the molecule. The number of rotatable bonds relates to molecular flexibility, while hydrogen bond donors and acceptors influence interactions with biological targets. Molar refractivity provides insight into molecular volume and polarizability; surface area reflects spatial occupancy, and TPSA correlates with the compound&#8217;s ability to cross biological membranes [<xref rid="B23-molecules-30-02858" ref-type="bibr">23</xref>,<xref rid="B24-molecules-30-02858" ref-type="bibr">24</xref>,<xref rid="B26-molecules-30-02858" ref-type="bibr">26</xref>,<xref rid="B27-molecules-30-02858" ref-type="bibr">27</xref>,<xref rid="B28-molecules-30-02858" ref-type="bibr">28</xref>].</p><p>Analysis of these pharmacokinetic and ADMET properties allowed for a comprehensive assessment of the drug-likeness and therapeutic potential of the selected compounds, highlighting key factors that could influence their pharmacological behavior. The evaluated compounds included SCOP, GAL, and the major constituents of FVEO: <italic toggle="yes">trans</italic>-anethole (58.1%), camphor (21.3%), <italic toggle="yes">trans</italic>-sabinene hydrate (3.1%), (+)-carvone (7.8%), and <italic toggle="yes">&#946;</italic>-pinene (2.6%), as identified in our previous study [<xref rid="B25-molecules-30-02858" ref-type="bibr">25</xref>]. ADMET predictions obtained from SwissADME, ADMETlab 2.0, and pKCSM revealed promising absorption, distribution, metabolism, excretion, and toxicity profiles (<xref rid="molecules-30-02858-t002" ref-type="table">Table 2</xref>).</p><p>All compounds demonstrated high human intestinal absorption (HIA), with values ranging from 72.626% for SCOP to 94.994% for GAL, and between 94.786% and 97.702% for the FVEO constituents, exceeding the recommended minimum threshold of 30%, and suggesting efficient intestinal absorption. Among the analyzed compounds, only SCOP was identified as a substrate for P-glycoprotein (P-gp), which could limit its intracellular retention by promoting efflux. Nevertheless, all compounds were predicted to be P-gp inhibitors, supporting their potential for enhanced bioavailability.</p><p>The volume of distribution at steady state (VDss) predictions indicated that all compounds, including SCOP, GAL, and the FVEO components, exceeded the cutoff value of log VDss &gt; &#8722;0.15, suggesting moderate to high systemic distribution. The predicted unbound fraction in plasma (Fu), which affects drug availability and target binding, was lowest for <italic toggle="yes">trans</italic>-anethole (0.266) and <italic toggle="yes">&#946;</italic>-pinene (0.35), followed by GAL (0.36), SCOP (0.414), camphor (0.459), <italic toggle="yes">trans</italic>-sabinene hydrate (0.469), and (+)-carvone (0.53).</p><p>Blood&#8211;brain barrier (BBB) permeability assessments showed that SCOP and GAL had log BB values below the threshold of 0.1, indicating limited central nervous system (CNS) penetration. In contrast, all FVEO-derived compounds had log BB values between 0.529 and 0.818, exceeding the threshold of 0.3, suggesting favorable BBB permeability. Similarly, CNS penetration predictions (log PS) revealed poor permeability for SCOP (&#8211;3.031), while the remaining compounds showed moderate-to-good CNS access, with values above the threshold of &#8722;2.</p><p>Cytochrome P450 (CYP) interactions were also evaluated. Only SCOP and GAL were predicted to be substrates for CYP3A4, a key metabolic enzyme. None of the analyzed compounds were found to inhibit CYP1A2, indicating a potentially favorable metabolic profile with a low risk of CYP-mediated drug&#8211;drug interactions. Regarding excretion, all compounds exhibited acceptable predicted clearance values, supporting their potential for efficient elimination.</p><p>Toxicological predictions indicated that SCOP (&#8722;0.319), GAL (&#8722;0.423), and <italic toggle="yes">&#946;</italic>-pinene (0.371) had the highest predicted human toxicity, all below the toxicity threshold of log mg/kg/day &lt; 0.447. Camphor showed moderate toxicity (0.473), while <italic toggle="yes">trans</italic>-sabinene hydrate (0.637), (+)-carvone (0.775), and <italic toggle="yes">trans</italic>-anethole (0.824) exhibited lower toxicity profiles. Acute oral toxicity in rats (LD<sub>50</sub>) ranged from 1.653 mol/kg for camphor (highest toxicity) to 2.728 mol/kg for GAL (lowest toxicity). For chronic oral toxicity (LOAEL), SCOP and GAL showed the lowest tolerated doses (0.736 and 0.966 mg/kg/day, respectively), whereas (+)-carvone and trans-anethole exhibited the highest tolerable doses (2.28 and 2.217 mg/kg/day, respectively). Among the compounds studied, only GAL was predicted to pose a risk for hepatotoxicity. Regarding skin sensitization, SCOP and GAL were predicted to be non-sensitizing, whereas all FVEO constituents, except <italic toggle="yes">&#946;</italic>-pinene, showed potential to trigger allergic reactions in susceptible individuals.</p><p>Overall, the ADMET profiles of the tested compounds revealed favorable pharmacokinetic characteristics and manageable toxicity, supporting their potential for further development as pharmacological agents.</p><p>The intestinal environment provides several key features that influence drug.</p><p>It is essential to recognize that essential oils are inherently complex phytochemical mixtures, composed of numerous volatile and semi-volatile constituents that may interact in synergistic, additive, or even antagonistic ways. These interactions can substantially modulate the individual pharmacological activities of the components, making the overall bioactivity of the whole extract more than the sum of its parts. As such, while in silico predictive models, such as PASS or SwissADME, offer valuable preliminary insights into the drug-likeness, target pathways, and safety profiles of individual compounds, they fall short in capturing the multifactorial and dynamic nature of these interactions. Therefore, any conclusions derived from computational analysis should be interpreted with caution and not be extrapolated directly to the in vivo context without appropriate experimental validation. Nonetheless, in silico profiling serves a supportive role by helping to identify potentially bioactive constituents and by guiding hypothesis generation for further pharmacological investigation.</p><p>Moreover, although computational ADME-Tox simulations predicted favorable pharmacokinetic properties, including oral bioavailability, BBB permeability, and low toxicity for the major constituents of FVEO, this study did not include in vivo validation of these pharmacokinetic or toxicological aspects. As a result, key parameters such as systemic absorption, distribution to target tissues (especially the CNS), metabolic stability, routes of excretion, and potential for systemic toxicity or bioaccumulation remain unexplored.</p></sec><sec id="sec2dot2-molecules-30-02858"><title>2.2. The Similarities Between the Pharmacokinetic Properties of the Compounds</title><p>The SwissADME web server was employed to theoretically predict the drug-likeness of the compounds investigated in this study (<xref rid="molecules-30-02858-t003" ref-type="table">Table 3</xref>). This analysis included evaluation against key drug-likeness filters: Lipinski&#8217;s rule of five [<xref rid="B29-molecules-30-02858" ref-type="bibr">29</xref>], Weber&#8217;s rule [<xref rid="B30-molecules-30-02858" ref-type="bibr">30</xref>], Ghose&#8217;s rule [<xref rid="B31-molecules-30-02858" ref-type="bibr">31</xref>], and Egan&#8217;s Rule [<xref rid="B32-molecules-30-02858" ref-type="bibr">32</xref>]. Compounds that satisfied these criteria were considered the most promising candidates. Additionally, the bioavailability score, a critical factor in drug development, was assessed. This score reflects the probability that a compound will be orally bioavailable in humans and has been refined over time through extensive research conducted by leading pharmaceutical companies worldwide [<xref rid="B33-molecules-30-02858" ref-type="bibr">33</xref>]. Notably, small molecules that violate more than one of these rules are more likely to exhibit poor bioavailability and limited therapeutic potential [<xref rid="B27-molecules-30-02858" ref-type="bibr">27</xref>].</p><p>The predictive results indicate that only SCOP and GAL fully comply with all five pharmacokinetic filters&#8212;Lipinski, Ghose, Veber, Egan, and Muegge&#8212;without any significant violations. This comprehensive compliance suggests that SCOP and GAL possess favorable drug-like properties and may serve as promising candidates for further drug development. In contrast, the major natural constituents of FVEO, <italic toggle="yes">trans</italic>-anethole, camphor, <italic toggle="yes">trans</italic>-sabinene hydrate, (+)-carvone, and <italic toggle="yes">&#946;</italic>-pinene exhibited at least one violation of Ghose&#8217;s rule and two violations of Muegge&#8217;s rule. Notably, none of the FVEO-derived compounds violated Veber&#8217;s or Egan&#8217;s rule, and only &#946;-pinene showed a violation of Lipinski&#8217;s rule.</p><p>Despite these minor deviations, all compounds achieved an Abbott bioavailability score of 0.55, placing them in a moderate probability class for oral bioavailability. This suggests that while the natural compounds from FVEO may present some limitations regarding their pharmacokinetic profiles, they still possess potential as orally active agents. Nonetheless, these in silico predictions represent a preliminary evaluation. Experimental validation through in vitro and in vivo studies is essential to confirm the bioavailability and therapeutic feasibility of these compounds for future drug development.</p></sec><sec id="sec2dot3-molecules-30-02858"><title>2.3. Prediction of Activity Spectra for Scopolamine, Galantamine, Trans-Anethole, Camphor, Trans-Sabinene Hydrate, (+)-Carvone, and &#946;-Pinene</title><p>The investigated compounds, SCOP, GAL, <italic toggle="yes">trans</italic>-anethole, camphor, <italic toggle="yes">trans</italic>-sabinene hydrate, (+)-carvone, and <italic toggle="yes">&#946;</italic>-pinene were subjected to detailed in silico evaluations using web-based platforms to assess their bioactivity profiles and medicinal chemistry properties. The predicted bioactivity scores and relevant pharmacological features are summarized in <xref rid="molecules-30-02858-t004" ref-type="table">Table 4</xref>. The Prediction of Activity Spectra for Substances (PASS) platform provided <italic toggle="yes">Pa</italic> (probability of activity) and <italic toggle="yes">Pi</italic> (probability of inactivity) values for various biological effects. A <italic toggle="yes">Pa</italic> value &gt; 0.5 generally indicates a higher likelihood of the compound exhibiting a particular biological activity.</p><p>SCOP showed the highest predicted affinity as an antagonist of nicotinic acetylcholine receptors (nAChRs), although the <italic toggle="yes">Pa</italic> value remained below the significance threshold (<italic toggle="yes">Pa</italic> &gt; 0.5). For neuromuscular blocking activity on ACh, <italic toggle="yes">trans</italic>-anethole was the only compound exceeding the threshold (<italic toggle="yes">Pa</italic> = 0.594), followed by <italic toggle="yes">trans</italic>-sabinene hydrate (<italic toggle="yes">Pa</italic> = 0.483) and SCOP (<italic toggle="yes">Pa</italic> = 0.351). Notably, SCOP was the only compound predicted to act as a cholinergic antagonist (<italic toggle="yes">Pa</italic> = 0.713, <italic toggle="yes">Pi</italic> = 0.004), in line with its known pharmacodynamic profile. SCOP was also predicted to influence neurotrophic factor expression (<italic toggle="yes">Pa</italic> = 0.113), while camphor showed a slightly higher potential in this regard (<italic toggle="yes">Pa</italic> = 0.498, <italic toggle="yes">Pi</italic> = 0.041).</p><p>Several FVEO constituents, camphor, <italic toggle="yes">trans</italic>-sabinene hydrate, (+)-carvone, and <italic toggle="yes">&#946;</italic>-pinene were predicted to possess antidementia activity, with <italic toggle="yes">Pa</italic> values exceeding the threshold of 0.5. GAL and <italic toggle="yes">trans</italic>-anethole also showed potential antidementia activity, albeit with slightly lower confidence (<italic toggle="yes">Pa</italic> = 0.458 and 0.499, respectively). Conversely, SCOP was unlikely to exhibit antidementia effects (<italic toggle="yes">Pa</italic> = 0.285). However, SCOP demonstrated a high probability of inducing delirium (<italic toggle="yes">Pa</italic> = 0.900) and behavioral disturbances (<italic toggle="yes">Pa</italic> = 0.861), consistent with its anticholinergic activity. It also showed moderate potential to inhibit lipid peroxidase (<italic toggle="yes">Pa</italic> = 0.521) and NADPH peroxidase (<italic toggle="yes">Pa</italic> = 0.431).</p><p>Among FVEO compounds, <italic toggle="yes">&#946;</italic>-pinene (<italic toggle="yes">Pa</italic> = 0.521), camphor (<italic toggle="yes">Pa</italic> = 0.495), and <italic toggle="yes">trans</italic>-anethole (<italic toggle="yes">Pa</italic> = 0.485) were predicted to have antineurotic properties. Anti-inflammatory potential was observed for trans-sabinene hydrate (<italic toggle="yes">Pa</italic> = 0.839), <italic toggle="yes">&#946;</italic>-pinene (<italic toggle="yes">Pa</italic> = 0.611), and <italic toggle="yes">trans</italic>-anethole (<italic toggle="yes">Pa</italic> = 0.526). Interestingly, GAL and <italic toggle="yes">trans</italic>-sabinene hydrate showed a moderate likelihood of inducing delirium (<italic toggle="yes">Pa</italic> = 0.612 and 0.622, respectively), and all tested compounds tended to cause behavioral disturbances. Additionally, GAL (<italic toggle="yes">Pa</italic> = 0.644), <italic toggle="yes">trans</italic>-anethole (<italic toggle="yes">Pa</italic> = 0.487), <italic toggle="yes">trans</italic>-sabinene hydrate (<italic toggle="yes">Pa</italic> = 0.450), and <italic toggle="yes">&#946;</italic>-pinene (<italic toggle="yes">Pa</italic> = 0.462) displayed potential antidepressant activity. Of all compounds, only <italic toggle="yes">trans</italic>-anethole was predicted to inhibit both lipid peroxidase (<italic toggle="yes">Pa</italic> = 0.439) and NADPH peroxidase (<italic toggle="yes">Pa</italic> = 0.488), indicating potential antioxidant properties.</p><p>These results provide a preliminary silico framework supporting the pharmacological relevance of the tested compounds, particularly those derived from FVEO. However, experimental validation remains essential to confirm their predicted bioactivities.</p></sec><sec id="sec2dot4-molecules-30-02858"><title>2.4. Effects of FVEO on Anxiety-like Behavior in NTT</title><p>To evaluate the effects of FVEO (25, 150, and 300 &#956;L/L) on anxiety-like behavior in SCOP (100 &#956;M)-exposed zebrafish using the novel tank test (NTT), specific behavioral parameters were recorded over a 6 min period per fish (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>). These included the number of entries into the top zone, time spent in the top zone (s), and latency to enter the top zone (s) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>B&#8211;D). Additionally, to assess general locomotor activity and differentiate it from anxiety-specific responses, total distance traveled (m), freezing duration (s), and swimming velocity (m/s) were measured (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>E&#8211;G).</p><p>In <xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>A, the effects of treatment with SCOP (100 &#956;M) and FVEO (25, 150, and 300 &#956;L/L) on anxiety-like behavior in zebrafish are illustrated. The figure highlights locomotor behavior in both the top and bottom zones of the tank, providing insight into how these treatments influence vertical exploration and anxiety-related responses. Notably, zebrafish exposed to different FVEO concentrations displayed distinct behavioral patterns, suggesting dose-dependent modulation of anxiety-like behavior.</p><p>A one-way ANOVA revealed a significant main effect of treatment on the number of entries into the top zone (F(5, 54) = 2.33, <italic toggle="yes">p</italic> &lt; 0.0001) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>B), with SCOP-treated zebrafish (group VI) showing a markedly reduced number of entries compared to the control group (group I). Similarly, there was a significant main effect of treatment on the time spent in the top zone (F(5, 54) = 1.61, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>C), with SCOP-exposed fish spending less time in the top zone of the tank. Latency to first entry into the top zone was also significantly affected by the treatment (F(5, 54) = 3.70, <italic toggle="yes">p</italic> &lt; 0.0001) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>D), with SCOP-treated zebrafish showing increased latency, further indicating heightened anxiety-like behavior.</p><p>In addition to vertical exploration, SCOP significantly altered locomotor activity. Total distance traveled was reduced (F(5, 54) = 0.93, <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>E), while freezing duration increased (F(5, 54) = 1.66, <italic toggle="yes">p</italic> &lt; 0.01) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>F), and average velocity decreased (F(5, 54) = 1.10, <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>G). These results demonstrate that SCOP exerts a pronounced anxiogenic effect in zebrafish, reflected by impaired exploration and reduced locomotor activity.</p><p>Despite its anxiogenic effects in preclinical models, it is important to note that SCOP has demonstrated anxiolytic and antidepressant properties in clinical settings. In human populations diagnosed with depression and bipolar disorder, SCOP has shown efficacy in reducing depressive symptoms and has been associated with significant anxiolytic effects [<xref rid="B33-molecules-30-02858" ref-type="bibr">33</xref>]. In contrast, findings from rodent models have been inconsistent. For example, Hughes and Otto [<xref rid="B34-molecules-30-02858" ref-type="bibr">34</xref>], reported that SCOP-treated rats displayed increased anxiety levels in behavioral tests such as the open field and light/dark test assays. Interestingly, in zebrafish, Hamilton et al. [<xref rid="B35-molecules-30-02858" ref-type="bibr">35</xref>] observed that treatment with a high concentration of SCOP (800 &#956;M) increased exploration of the top zone in the NTT, suggesting anxiolytic-like effects. However, other studies have consistently identified SCOP as a robust model for anxiety and cognitive impairment in zebrafish, making it a reliable tool for neurobehavioral assessment [<xref rid="B36-molecules-30-02858" ref-type="bibr">36</xref>,<xref rid="B37-molecules-30-02858" ref-type="bibr">37</xref>,<xref rid="B38-molecules-30-02858" ref-type="bibr">38</xref>,<xref rid="B39-molecules-30-02858" ref-type="bibr">39</xref>,<xref rid="B40-molecules-30-02858" ref-type="bibr">40</xref>]. These discrepancies highlight the complexity of SCOP&#8217;s neuropharmacological profile, which appears to be influenced by species differences, dosage, administration route, and exposure duration. In the present study, administration of FVEO to zebrafish acutely exposed to SCOP significantly modulated anxiety-like behavior. Notably, only the lowest FVEO concentration (25 &#956;L/L) resulted in a significant increase in the number of entries into the top zone (<italic toggle="yes">p</italic> &lt; 0.01), resembling the effect observed with GAL treatment (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>B). Similarly, only zebrafish in group VIII (25 &#956;L/L FVEO) showed a significant increase in time spent in the top zone (<italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>C). In contrast, latency to first entry into the top zone significantly increased at all tested FVEO concentrations (<italic toggle="yes">p</italic> &lt; 0.01 for 25 and 150 &#956;L/L, <italic toggle="yes">p</italic> &lt; 0.05 for 300 &#956;L/L), compared to the SCOP-only group (VI) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>D). Importantly, chronic exposure to FVEO (25, 150, and 300 &#956;L/L for 9 days) did not significantly affect total distance traveled (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>E), freezing duration (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>F), or average velocity (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>G), indicating that FVEO does not impair general locomotor function. Our previous findings in a rodent model of AD [<xref rid="B26-molecules-30-02858" ref-type="bibr">26</xref>] further support the anxiolytic potential of FVEO. In that study, inhalation of FVEO (1% and 3%) for 60 min daily over 21 days significantly increased the time spent in the open arms of the elevated plus maze in A&#946; (1&#8211;42)-treated Wistar rats, particularly at the higher concentration (3%). The observed differences between models may reflect species&#8211;specific sensitivities to FVEO constituents or divergent pharmacodynamic responses. It is plausible that zebrafish, due to their aquatic environment and gill-based exposure pathways, are more sensitive to higher FVEO concentrations, which may attenuate or reverse the anxiolytic effects observed at lower doses.</p><p>The anxiolytic and antidepressant properties of <italic toggle="yes">F. vulgare</italic> have also been corroborated in clinical and preclinical studies. Alvarado-Garc&#237;a et al. [<xref rid="B41-molecules-30-02858" ref-type="bibr">41</xref>], reported significant reductions in anxiety and depression using Zung&#8217;s Self-Rating Scales following administration of essential oils from <italic toggle="yes">F. vulgare</italic> aerial parts and seeds. Similarly, Raman et al. [<xref rid="B42-molecules-30-02858" ref-type="bibr">42</xref>] demonstrated that FVEO and its major component, <italic toggle="yes">trans</italic>-anethole, reduced anxiety-like behavior in rats subjected to social isolation stress in the elevated plus maze. Moreover, Bahari et al. [<xref rid="B43-molecules-30-02858" ref-type="bibr">43</xref>] suggested that <italic toggle="yes">trans</italic>-anethole may act as an anti-stress agent by inhibiting key hypothalamic stress pathways, such as corticotropin-releasing hormone (CRH) and calcitonin gene-related peptide (CGRP).</p></sec><sec id="sec2dot5-molecules-30-02858"><title>2.5. Effects of FVEO on Zebrafish Spatial Memory Assessed in the Y-Maze Test</title><p>To investigate the effects of FVEO on spatial memory and novelty-induced behavior, zebrafish were subjected to the Y-maze test (<xref rid="molecules-30-02858-f002" ref-type="fig">Figure 2</xref>). The evaluated behavioral parameters included distance traveled (m), spontaneous alternation percentage (%), turn angle (&#176;), and time spent in the novel arm (s). <xref rid="molecules-30-02858-f002" ref-type="fig">Figure 2</xref>A presents representative locomotor trajectories, highlighting the distinct movement patterns exhibited by zebrafish across the different experimental groups.</p><p>In the Y-maze, Tukey&#8217;s post hoc analyses revealed that SCOP-treated zebrafish (Group VI) showed a decrease in total distance traveled (<italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="molecules-30-02858-f002" ref-type="fig">Figure 2</xref>B) and a smaller turning angle (<italic toggle="yes">p</italic> &lt; 0.01) (<xref rid="molecules-30-02858-f002" ref-type="fig">Figure 2</xref>D) compared to the control group (Group I), suggesting the induction of a hypolocomoric effect by SCOP. Simultaneously, group VI showed a lower percentage of spontaneous alternation (<italic toggle="yes">p</italic> &lt; 0.01) (<xref rid="molecules-30-02858-f002" ref-type="fig">Figure 2</xref>C) and spent less time in the novel arm (<italic toggle="yes">p</italic> &lt; 0.05) compared to the control group (Group I) (<xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>E). These findings align with those reported by Volgin et al. [<xref rid="B44-molecules-30-02858" ref-type="bibr">44</xref>], who showed that exposure of zebrafish to SCOP (100 &#181;M) reduces the number of top zone entries in the NTT and the maximum velocity of zebrafish, thus suggesting hypoactive behavior and manifestations of anxiety. Similarly, Pande et al. [<xref rid="B45-molecules-30-02858" ref-type="bibr">45</xref>], described hypolocomotor and amnesic effects of SCOP in zebrafish using the T-maze test. While the SCOP-induced zebrafish model provides a well-characterized platform for evaluating short-term cognitive impairment and neurochemical disruptions, it does not fully recapitulate the progressive and multifactorial nature of AD. In particular, the deficits induced by SCOP are acute and pharmacologically reversible, lacking the chronic neuropathological features such as amyloid-&#946; deposition, tauopathy, and sustained neuroinflammation. Therefore, the findings reported here reflect the acute neuroprotective and antioxidant actions of FVEO and should be interpreted in the context of early-phase cognitive decline. Further validation in chronic mammalian models of AD is required to support translational applicability.</p><p>Although no significant behavioral changes were observed in zebrafish treated with FVEO alone (Groups II&#8211;V) compared to the control group (Group I), significant differences were found between the SCOP-only group (Group VI) and the FVEO + SCOP groups (Groups VII&#8211;X). FVEO treatment in SCOP-exposed zebrafish enhanced locomotor activity, as evidenced by increased total distance traveled (<italic toggle="yes">p</italic> &lt; 0.05 for 150 &#181;L/L; <xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>B) and greater turn angle (<italic toggle="yes">p</italic> &lt; 0.01 for 25, 150, and 300 &#181;L/L; <xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>D). Moreover, both GAL (1 mg/L) and FVEO (25, 150, and 300 &#181;L/L) significantly improved exploratory behavior, as demonstrated by increased time spent in the novel arm (<italic toggle="yes">p</italic> &lt; 0.05 for GAL; <italic toggle="yes">p</italic> &lt; 0.001 for 25 &#181;L/L FVEO; <italic toggle="yes">p</italic> &lt; 0.01 for 150 and 300 &#181;L/L FVEO; <xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>E) and enhanced spontaneous alternation (<italic toggle="yes">p</italic> &lt; 0.001 for 25 &#181;L/L; <italic toggle="yes">p</italic> &lt; 0.05 for 150 and 300 &#181;L/L; <xref rid="molecules-30-02858-f001" ref-type="fig">Figure 1</xref>C), compared to SCOP-only zebrafish.</p><p>The memory-enhancing effects of <italic toggle="yes">F. vulgare</italic> have also been reported in previous studies. Delaram et al. [<xref rid="B46-molecules-30-02858" ref-type="bibr">46</xref>] demonstrated that <italic toggle="yes">F. vulgare</italic> extract improved cognitive performance in an A&#946;-induced rat model of AD. Similarly, Bhatti et al. [<xref rid="B47-molecules-30-02858" ref-type="bibr">47</xref>] highlighted the neuroprotective potential of <italic toggle="yes">F. vulgare</italic> in a mouse model of lead-induced cerebral neurotoxicity, showing that treatment normalized the expression of amyloid precursor protein (APP) isoforms and oxidative stress markers.</p></sec><sec id="sec2dot6-molecules-30-02858"><title>2.6. Effects of FVEO on Recognition Memory Assessed in the NOR Test</title><p>To evaluate the effects of FVEO on recognition memory in acutely SCOP-treated zebrafish, the novel object recognition (NOR) test was employed. The test involved the use of complex geometric objects&#8212;specifically, a familiar yellow cube and a novel blue cube&#8212;to assess the ability of zebrafish to discriminate between familiar (F) and novel (N) stimuli. <xref rid="molecules-30-02858-f003" ref-type="fig">Figure 3</xref>A shows representative locomotor patterns recorded during the test across different experimental groups. Tukey&#8217;s post hoc analysis revealed a significant reduction in preference for the novel object in the SCOP-treated group (<italic toggle="yes">p</italic> &lt; 0.001; <xref rid="molecules-30-02858-f003" ref-type="fig">Figure 3</xref>B) compared to the control group, indicating a SCOP-induced impairment in recognition memory. These findings are in line with our previous results demonstrating the amnesic effects of SCOP in zebrafish [<xref rid="B48-molecules-30-02858" ref-type="bibr">48</xref>].</p><p>No statistically significant differences were observed between zebrafish treated with FVEO alone (Groups III&#8211;V) and the control group (Group I). However, a trend toward increased preference for the novel object was noted in the FVEO (150 &#181;L/L)-treated group (Group IV), as shown in <xref rid="molecules-30-02858-f003" ref-type="fig">Figure 3</xref>B. In contrast, Tukey&#8217;s post hoc analysis revealed significant improvements in recognition memory in zebrafish chronically treated with FVEO (25, 150, and 300 &#181;L/L) followed by acute SCOP administration (Groups VIII&#8211;X) compared to the SCOP-only group (Group VI). The most pronounced effects were observed at 25 and 150 &#181;L/L FVEO (<italic toggle="yes">p</italic> &lt; 0.0001), while 300 &#181;L/L also produced a significant improvement (<italic toggle="yes">p</italic> &lt; 0.001), as indicated by the increased preference for the novel object (<xref rid="molecules-30-02858-f003" ref-type="fig">Figure 3</xref>B).</p><p>These findings are consistent with previous reports. Memory-enhancing effects of <italic toggle="yes">F. vulgare</italic> extract (50, 100, and 200 mg/kg, administered orally) were demonstrated in a SCOP-induced Wistar rat model of cognitive impairment (1 mg/kg, i.p.) [<xref rid="B49-molecules-30-02858" ref-type="bibr">49</xref>]. Additionally, Chang et al. [<xref rid="B50-molecules-30-02858" ref-type="bibr">50</xref>] reported that <italic toggle="yes">trans</italic>-anethole, a major component of FVEO, facilitates long-term potentiation (LTP) through both NMDA receptor-dependent and -independent mechanisms, and mitigates trimethyltin-induced LTP impairment. These findings suggest that <italic toggle="yes">trans</italic>-anethole may regulate hippocampal synaptic plasticity and could have therapeutic potential for cognitive dysfunction associated with neurodegenerative diseases such as AD.</p></sec><sec id="sec2dot7-molecules-30-02858"><title>2.7. Effects of FVEO on AChE Activity</title><p>Cholinergic neurotransmission plays a central role in cognitive function, and its disruption is a hallmark of AD. In the early stages of AD, which typically present with progressive short-term memory loss, there is a selective degeneration of cholinergic neurons in the basal forebrain. Consequently, many pharmacological strategies for AD treatment focus on enhancing cholinergic function [<xref rid="B51-molecules-30-02858" ref-type="bibr">51</xref>]. AChEIs are designed to mitigate the cholinergic deficit underlying cognitive and neuropsychiatric symptoms in AD by inhibiting the breakdown of ACh. ACh-positive neurons project widely to the cortex, modulating cortical processing and responses to novel stimuli. Beyond its role in terminating cholinergic neurotransmission, AChE has been implicated in broader pathophysiological processes, including the regulation of other proteins, regional cerebral blood flow, tau phosphorylation, and the amyloid cascade-factors that may influence AD progression [<xref rid="B52-molecules-30-02858" ref-type="bibr">52</xref>].</p><p>To explore the potential mechanism by which FVEO (25, 150, and 300 &#181;L/L) mitigates SCOP-induced memory deficits, AChE activity was assessed in zebrafish brain homogenates. As shown in <xref rid="molecules-30-02858-f004" ref-type="fig">Figure 4</xref>, SCOP-treated zebrafish (Group VI) exhibited a significant increase in AChE activity compared to the control group (Group I) (<italic toggle="yes">p</italic> &lt; 0.001), indicating enhanced cholinergic breakdown and supporting the involvement of the cholinergic system in SCOP-induced cognitive impairment.</p><p>However, chronic administration of FVEO significantly reduced AChE activity in SCOP-treated zebrafish at all tested concentrations (25, 150, and 300 &#181;L/L; <italic toggle="yes">p</italic> &lt; 0.0001), compared to the SCOP-only group (Group VI). Notably, FVEO at 25 &#181;L/L also modulated AChE activity when administered alone, suggesting a direct inhibitory effect. These findings indicate that FVEO may exert protective effects against SCOP-induced cholinergic dysfunction by modulating AChE activity.</p><p>Previous studies support these observations. Abdel-Baki et al. [<xref rid="B53-molecules-30-02858" ref-type="bibr">53</xref>] reported the inhibitory effects of FVEO and its major components, <italic toggle="yes">trans</italic>-anethole and fenchone, on AChE activity in different developmental stages of <italic toggle="yes">Musca domestica</italic>. Similarly, Joshi et al. [<xref rid="B54-molecules-30-02858" ref-type="bibr">54</xref>] demonstrated that an eight-day oral administration of methanolic extract from the whole plant of <italic toggle="yes">F. vulgare</italic> Linn. attenuated SCOP (0.4 mg/kg)-induced memory impairment and age-related cognitive decline in mice, partly through regulation of AChE activity. Additionally, <italic toggle="yes">trans</italic>-anethole has been shown to possess anti-AChE properties in <italic toggle="yes">Ephestia kuehniella</italic> Zeller [<xref rid="B55-molecules-30-02858" ref-type="bibr">55</xref>], further supporting its potential role in modulating cholinergic pathways.</p></sec><sec id="sec2dot8-molecules-30-02858"><title>2.8. Effects of FVEO on the Antioxidant System Activity</title><p>Oxidative stress results from an imbalance between oxidants and antioxidants, favoring the accumulation of reactive species. This imbalance may stem from excessive free radical production or diminished antioxidant capacity. Molecular oxygen reduction sequentially generates superoxide anions and hydrogen peroxide, which can further convert into highly reactive hydroxyl radicals, collectively termed reactive oxygen species (ROS). These ROS interact with cellular macromolecules, including lipids, proteins, and nucleic acids, altering their structure and function [<xref rid="B56-molecules-30-02858" ref-type="bibr">56</xref>]. The brain is particularly vulnerable to oxidative damage due to its high oxygen consumption, abundant lipid content, and limited antioxidant capacity. Oxidative damage in the brain is exacerbated by mitochondrial dysfunction, elevated metal ion concentrations, inflammation, and A&#946; accumulation [<xref rid="B57-molecules-30-02858" ref-type="bibr">57</xref>]. In AD, oxidative stress has been implicated as a key pathological event, affecting both characteristic lesions (senile plaques and neurofibrillary tangles) and morphologically normal neurons [<xref rid="B58-molecules-30-02858" ref-type="bibr">58</xref>]. Consequently, oxidative stress is considered an early and central mechanism in AD pathogenesis, and antioxidant-based interventions may offer therapeutic potential [<xref rid="B57-molecules-30-02858" ref-type="bibr">57</xref>].</p><p>To explore the potential antioxidant effects of FVEO, the activities of key enzymatic antioxidants, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX), were measured, along with reduced glutathione (GSH) content, protein carbonyl levels, and malondialdehyde (MDA) concentrations in zebrafish brain tissue. Acute SCOP exposure (100 &#181;M, 30 min) significantly impaired oxidative status compared to control zebrafish (Group I), with reductions in SOD (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>A), CAT (<italic toggle="yes">p</italic> &lt; 0.01; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>B), and GPX activity (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>C), along with decreased GSH content (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>D). SCOP also increased oxidative damage, reflected by elevated carbonyl protein (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>E) and MDA levels (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>F). These results are consistent with previous studies showing that SCOP induces oxidative stress and disrupts the cholinergic system in both rodents [<xref rid="B59-molecules-30-02858" ref-type="bibr">59</xref>,<xref rid="B60-molecules-30-02858" ref-type="bibr">60</xref>] and zebrafish [<xref rid="B40-molecules-30-02858" ref-type="bibr">40</xref>]. Additionally, SCOP has been shown to suppress Nrf2 expression and impair CREB/BDNF signaling, contributing to decreased synaptic plasticity and antioxidant defense [<xref rid="B61-molecules-30-02858" ref-type="bibr">61</xref>,<xref rid="B62-molecules-30-02858" ref-type="bibr">62</xref>,<xref rid="B63-molecules-30-02858" ref-type="bibr">63</xref>].</p><p>No significant differences were observed between zebrafish treated with FVEO alone (Groups III&#8211;V) and the control group (Group I) regarding antioxidant enzyme activity or oxidative stress markers. However, FVEO treatment (25, 150, and 300 &#181;L/L) significantly improved oxidative parameters in SCOP-treated zebrafish (Groups VIII&#8211;X). Specifically, SOD activity was restored at all concentrations (<italic toggle="yes">p</italic> &lt; 0.001 for 25 &#181;L/L, <italic toggle="yes">p</italic> &lt; 0.01 for 150 &#181;L/L, and <italic toggle="yes">p</italic> &lt; 0.05 for 300 &#181;L/L; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>A). CAT activity was also significantly increased at 25 &#181;L/L (<italic toggle="yes">p</italic> &lt; 0.01) and 150 &#181;L/L (<italic toggle="yes">p</italic> &lt; 0.05), but not at 300 &#181;L/L (<xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>B). GPX activity was enhanced at all concentrations (<italic toggle="yes">p</italic> &lt; 0.01 for 25 and 150 &#181;L/L; <italic toggle="yes">p</italic> &lt; 0.05 for 300 &#181;L/L; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>C). Additionally, GSH content was restored at 25 and 150 &#181;L/L (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>D). FVEO significantly reduced carbonyl protein levels at all concentrations (<italic toggle="yes">p</italic> &lt; 0.001), like the effect observed with GAL (<italic toggle="yes">p</italic> &lt; 0.05; <xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>E). Interestingly, only the lowest concentration of FVEO (25 &#181;L/L) significantly attenuated MDA levels (<italic toggle="yes">p</italic> &lt; 0.05), suggesting that lower doses may be more effective in preventing lipid peroxidation (<xref rid="molecules-30-02858-f005" ref-type="fig">Figure 5</xref>F).</p><p>The antioxidant and neuroprotective effects of FVEO observed in this study, reflected by the reduction in MDA levels and the restoration of endogenous antioxidant enzyme activities (SOD, CAT, GPx), suggest the involvement of cellular redox-regulating mechanisms. However, specific molecular pathways that may mediate these effects, such as the Nrf2&#8211;ARE signaling axis, known for its pivotal role in the transcriptional activation of antioxidant genes or the CREB-dependent pathway, implicated in neuroprotection, synaptic plasticity, and memory consolidation, were not explored [<xref rid="B64-molecules-30-02858" ref-type="bibr">64</xref>].</p><p>It is important to note that, although the present data do not include direct molecular analyses, the existing literature provides supporting evidence for the involvement of the Nrf2-ARE axis in the effects of <italic toggle="yes">F. vulgare</italic>. For instance, in a UVB-induced skin photoaging model, extracts from <italic toggle="yes">F. vulgare</italic> have been shown to stimulate nuclear translocation of Nrf2 and enhance the expression of antioxidant enzymes such as GSH in human fibroblast cells and skin tissues of animal models, highlighting the activation of this cytoprotective pathway [<xref rid="B65-molecules-30-02858" ref-type="bibr">65</xref>]. Therefore, it can be hypothesized that FVEO exerts its antioxidant effects in part through the activation of the Nrf2 signaling pathway. However, to confirm this mechanism in a neurodegenerative context, further studies incorporating gene expression profiling and proteomic analyses are warranted. Nonetheless, external evidence supports the modulation of this antioxidant axis by major FVEO constituents. For example, trans-anethole significantly activated Nrf2 and upregulated the expression of cytoprotective antioxidant enzymes such as SOD and GPx in the intestines of infected broiler chickens (600 mg/kg diet; <italic toggle="yes">p</italic> &lt; 0.05), demonstrating a positive regulatory effect on the Nrf2-ARE pathway [<xref rid="B66-molecules-30-02858" ref-type="bibr">66</xref>]. Similarly, &#945;-pinene has been shown to modulate memory by activating the BDNF/TrkB/CREB signaling pathway in epilepsy models, indicating the potential of monoterpene compounds to influence neurotrophic signaling mechanisms [<xref rid="B67-molecules-30-02858" ref-type="bibr">67</xref>]. Therefore, there is substantial evidence suggesting that despite the lack of direct experimental validation in the zebrafish model, the major constituents of FVEO may activate the Nrf2-ARE axis and, at least indirectly, modulate the CREB&#8211;BDNF pathway. The studies cited provide mechanistic support and a theoretical framework for interpreting our findings, particularly, the optimal effects observed at the lowest tested dose (25 &#181;L/L) which may be attributed to hormesis and efficient activation of these stress-responsive intracellular signaling cascades.</p><p>These findings are supported by earlier studies. FVEO pretreatment has been shown to inhibit cyclophosphamide-induced cytotoxicity in mouse bone marrow cells by reducing micronuclei formation and enhancing antioxidant enzyme activities, including SOD, CAT, and GSH, while lowering MDA levels in the liver [<xref rid="B68-molecules-30-02858" ref-type="bibr">68</xref>]. Barakat et al. [<xref rid="B69-molecules-30-02858" ref-type="bibr">69</xref>] also reported that <italic toggle="yes">F. vulgare</italic> seeds and sprouts contain phenolic and volatile compounds capable of preventing oxidative DNA damage and ameliorating CCl<sub>4</sub>-induced hepatotoxicity in rats. Moreover, Imran et al. [<xref rid="B70-molecules-30-02858" ref-type="bibr">70</xref>], demonstrated that <italic toggle="yes">F. vulgare</italic> extract promotes functional recovery and reduces oxidative stress in a mouse model of sciatic nerve injury.</p></sec><sec id="sec2dot9-molecules-30-02858"><title>2.9. Correlation Analyses Between Behavioral and Biochemical Parameters</title><p>The results obtained from Pearson&#8217;s correlation analysis provide valuable insights into the relationships between behavioral outcomes and oxidative stress markers in zebrafish. A significant negative correlation was observed between the time spent in the top zone during the NTT and MDA levels (r = &#8722;0.6683, <italic toggle="yes">p</italic> &lt; 0.0001; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>A), suggesting that increased exploratory behavior is associated with reduced lipid peroxidation. This finding supports the hypothesis that FVEO may exert anxiolytic effects partly through its antioxidant properties.</p><p>Similarly, a significant negative correlation was found between the time spent in the novel arm of the Y-maze and MDA levels (r = &#8722;0.5218, <italic toggle="yes">p</italic> &lt; 0.01; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>B), indicating that enhanced spatial exploration correlates with lower oxidative damage. This further supports the role of FVEO in mitigating SCOP-induced oxidative stress and improving cognitive function.</p><p>A particularly strong negative correlation was observed between the percentage of preference for the novel object in the NOR test and MDA levels (r = &#8722;0.7620, <italic toggle="yes">p</italic> &lt; 0.0001; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>C), suggesting that improved recognition memory is associated with reduced lipid peroxidation. Collectively, these findings highlight a potential link between the behavioral improvements induced by FVEO and its antioxidative capacity, specifically in reducing MDA, a key marker of oxidative damage.</p><p>A significant negative correlation was also identified between SOD activity and MDA levels (r = &#8722;0.6683, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>E), suggesting that higher SOD activity is associated with reduced lipid peroxidation. This finding supports the potential protective role of SOD against oxidative damage. In contrast, AChE activity and the level of carbonylated proteins showed significant positive correlations with MDA levels. Specifically, a strong positive correlation was observed between AChE activity and MDA (r = 0.6152, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>D), as well as between carbonylated protein levels and MDA (r = 0.6844, <italic toggle="yes">p</italic> &lt; 0.0001; <xref rid="molecules-30-02858-f006" ref-type="fig">Figure 6</xref>F). These results imply a possible link between increased oxidative stress, enhanced AChE activity, and protein oxidation, further supporting the hypothesis that lipid peroxidation is associated with cholinergic dysfunction and oxidative damage in SCOP-treated zebrafish.</p><p>These findings are in line with the previous literature demonstrating the neuroprotective and antioxidant effects of major FVEO constituents. Ryu et al. [<xref rid="B71-molecules-30-02858" ref-type="bibr">71</xref>] reported that sabinene mitigates ROS-induced skeletal muscle atrophy via modulation of the MAPK/MuRF-1 pathway, indicating its capacity to counter oxidative stress. Dhingra et al. [<xref rid="B72-molecules-30-02858" ref-type="bibr">72</xref>] demonstrated that <italic toggle="yes">trans</italic>-anethole possesses significant antidepressant activity in both stressed and non-stressed mice, likely mediated by inhibition of monoamine oxidase A (MAO-A), reduction in oxidative stress markers such as plasma nitrite and brain MDA, and increases in GSH and CAT levels. The reversal of corticosterone elevation also contributed to its antidepressant effects.</p><p>Similarly, Salama et al. [<xref rid="B73-molecules-30-02858" ref-type="bibr">73</xref>] showed that camphor exerts antioxidant and anti-inflammatory effects by enhancing CAT and Nrf2 activity while reducing nitric oxide (NO), MDA, TNF-&#945;, and TLR4 levels. Camphor also increased neurotransmitter levels (serotonin, dopamine, GABA) and neuronal signaling proteins in a model of ciprofloxacin-induced neurotoxicity. Dai et al. [<xref rid="B74-molecules-30-02858" ref-type="bibr">74</xref>] reported that <italic toggle="yes">d</italic>-carvone significantly improved outcomes in a rat model of cerebral ischemia/reperfusion injury by reducing brain edema and infarct size, improving neurological scores, and exerting antioxidant, anti-inflammatory, and anti-apoptotic effects through modulation of pro-inflammatory cytokines and apoptotic pathways. Additionally, Dahiya et al. [<xref rid="B75-molecules-30-02858" ref-type="bibr">75</xref>] demonstrated that <italic toggle="yes">&#946;</italic>-pinene reversed cognitive impairment induced by intracerebroventricular streptozotocin (ICV-STZ) in mice, without affecting locomotor function. &#946;-Pinene normalized mitochondrial enzyme activities (complexes I&#8211;IV), reduced AChE activity, and restored antioxidant parameters (GSH, CAT, SOD), while decreasing lipid peroxidation in the cortex and hippocampus.</p><p>Taken together, these findings suggest that FVEO may exert therapeutic effects through multifaceted mechanisms involving behavioral improvements and attenuation of oxidative stress. The observed correlations between behavioral performance, enzymatic antioxidant activity, and lipid peroxidation markers underscore the complexity of the neuroprotective effects of FVEO. Its impact on cholinergic function and oxidative balance positions it as a promising candidate for mitigating symptoms associated with amnesia and anxiety.</p></sec></sec><sec id="sec3-molecules-30-02858"><title>3. Materials and Methods</title><sec id="sec3dot1-molecules-30-02858"><title>3.1. Estimated In Silico Pharmacokinetic Profile of Compounds</title><p>In the computational analysis, we employed a simplified approach to represent chemical structures using the canonical Simplified Molecular Input Line Entry System (SMILES) notation for SCOP, GAL, and the principal constituents of FVEO, including <italic toggle="yes">&#946;</italic>-pinene, <italic toggle="yes">trans</italic>-sabinene hydrate, camphor, (+)-carvone, and <italic toggle="yes">trans</italic>-anethole (<xref rid="molecules-30-02858-f007" ref-type="fig">Figure 7</xref>). The chemical composition of FVEO was previously characterized using an Agilent 6890 GC-MS system (Santa Clara, CA, USA) equipped with a split/splitless injector, as described in detail elsewhere [<xref rid="B25-molecules-30-02858" ref-type="bibr">25</xref>]. Canonical SMILES data were retrieved from the PubChem database in November 2023.</p><p>To predict and evaluate the pharmacokinetic and physicochemical properties of these compounds, we used three freely available computational platforms: SwissADME [<xref rid="B22-molecules-30-02858" ref-type="bibr">22</xref>], pKCSM [<xref rid="B23-molecules-30-02858" ref-type="bibr">23</xref>], and ADMETlab 2.0 [<xref rid="B24-molecules-30-02858" ref-type="bibr">24</xref>]. These tools provide in silico predictions for key pharmacological parameters such as solubility (log S), absorption, distribution, metabolism, excretion, and toxicity (ADMET). To ensure consistency across different platforms and to facilitate meaningful comparisons with experimental data, we standardized measurement units for parameters such as solubility and clearance. Additionally, parameters such as absorption and permeability were converted into binary categories (e.g., &#8220;Yes/No&#8221;) due to differing classification criteria used by the platforms. This standardized and methodical approach allowed for objective interpretation of predictive data, enhancing the reliability of comparisons between computational results and experimental findings, and supporting the evaluation of the pharmacological potential of the selected compounds.</p><p>The selected predictive parameters included: (1) human intestinal absorption, (2) P-glycoprotein substrate status, (3) P-glycoprotein I/II inhibition, (4) volume of distribution at steady state (VDss, human), (5) blood&#8211;brain barrier (BBB) permeability, (6) central nervous system (CNS) permeability, (7) CYP3A4 substrate status, (8) CYP1A2 inhibition, (9) total clearance, (10) maximum tolerated dose in humans, (11) oral acute toxicity in rats (LD<sub>50</sub>), (12) oral chronic toxicity in rats (LOAEL), and (13) hepatotoxicity and skin sensitization.</p></sec><sec id="sec3dot2-molecules-30-02858"><title>3.2. Prediction of the Biological Activity of the Compounds via PASS Online Platforms</title><p>The Prediction of Activity Spectra for Substances (PASS) online tool [<xref rid="B76-molecules-30-02858" ref-type="bibr">76</xref>] was used to estimate the potential biological activities and adverse effects of the tested compounds. PASS predictions are based on structure&#8211;activity relationships, analyzing the correlation between a compound&#8217;s chemical structure and its known biological activities. The following activity probabilities were selected for evaluation: ACh nicotinic antagonist, ACh neuromuscular blocking agent, cholinergic antagonist, neurotransmitter antagonist, neurotrophic factor enhancer, dementia treatment, antineurotic activity, anti-inflammatory activity, anti-delirium effect, behavioral disturbance modulation, antidepressant activity, lipid peroxidase inhibition, and inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) peroxidase.</p></sec><sec id="sec3dot3-molecules-30-02858"><title>3.3. Compound Prediction, Drug Analogy</title><p>To rigorously assess the drug-likeness and structural suitability of the investigated compounds, we employed the SwissADME online platform [<xref rid="B22-molecules-30-02858" ref-type="bibr">22</xref>], which enables comprehensive in silico evaluation based on established medicinal chemistry filters. The following drug-likeness rules were applied: Weber&#8217;s rule [<xref rid="B30-molecules-30-02858" ref-type="bibr">30</xref>], Lipinski&#8217;s rule of five [<xref rid="B29-molecules-30-02858" ref-type="bibr">29</xref>], Egan&#8217;s rule [<xref rid="B32-molecules-30-02858" ref-type="bibr">32</xref>], and Ghose&#8217;s rule [<xref rid="B31-molecules-30-02858" ref-type="bibr">31</xref>]. Lipinski&#8217;s rule of five evaluates oral bioavailability by setting limits on key molecular properties: molecular weight (&lt;500 Da), lipophilicity (Log P &lt; 5), hydrogen bond donors (&#8804;5), and hydrogen bond acceptors (&#8804;10). Weber&#8217;s rule focuses on molecular flexibility and polar surface area, recommending a maximum of 10 rotatable bonds and a topological polar surface area (TPSA) of &#8804; 140 &#197;. Ghose&#8217;s filter incorporates broader criteria, including molecular weight (160&#8211;480 Da), Log P (&#8722;0.4 to 5.6), molar refractivity (40&#8211;130), and total number of atoms (20&#8211;70), to define drug-likeness based on a wider physicochemical profile. Egan&#8217;s rule evaluates the potential for oral bioavailability based on Log P and TPSA values and provides insights into membrane permeability and absorption, also relevant for liver exposure and toxicity considerations.</p><p>Together, these structural filters help determine whether the compounds possess favorable physicochemical characteristics for further development as drug candidates and assess their safety and pharmacokinetic suitability in a medicinal context [<xref rid="B32-molecules-30-02858" ref-type="bibr">32</xref>].</p></sec><sec id="sec3dot4-molecules-30-02858"><title>3.4. Experimental Design and Ethical Considerations</title><p>This study aimed to evaluate the neuropharmacological effects of FVEO on cognitive performance, anxiety-like behavior, and oxidative status in zebrafish (<italic toggle="yes">Danio rerio</italic>). A total of 100 adult short-fin Tubingen wild-type zebrafish (5&#8211;7 months old) with a 1:1 male-to-female ratio were used. The animals were obtained from the European Zebrafish Resource Center (Institute of Toxicology and Genetics, Germany) and acclimated under quarantine for two weeks. Following quarantine, zebrafish were housed in groups of 10 per a 10 L tank containing dechlorinated water treated with Tetra AquaSafe (Melle, Germany) and replaced daily.</p><p>Environmental parameters were rigorously controlled: water temperature was maintained at 28 &#177; 2 &#176;C, pH at 7.0&#8211;8.0, dissolved oxygen at 8 &#177; 1 mg/L, conductivity at 1400&#8211;1500 &#181;S/cm, and ammonia and nitrite concentrations were maintained below 0.001 mg/L. A 14:10 h light&#8211;dark cycle was used, and fish were fed Norwin Norvital flakes three times daily (08:00, 14:00, and 20:00), with feeding adjusted to ensure complete consumption within 10 min.</p><p>Experimental procedures followed the ARRIVE guidelines [<xref rid="B77-molecules-30-02858" ref-type="bibr">77</xref>] for animal research and were approved by the Animal Ethics Committee of the Faculty of Biology, Alexandru Ioan Cuza University of Ia&#537;i, Romania (Project approval no. 370/4 February 2022). All procedures complied with Directive 2010/63/EU of the European Parliament and Council on the protection of animals used for scientific purposes. No animals exhibited signs of toxicity or mortality during the study.</p></sec><sec id="sec3dot5-molecules-30-02858"><title>3.5. Group Allocation and Treatment</title><p>Zebrafish were randomly assigned to 10 experimental groups (n = 10/group), as illustrated in <xref rid="molecules-30-02858-f008" ref-type="fig">Figure 8</xref>:<list list-type="bullet"><list-item><p><bold>Group I (Control):</bold> Untreated zebrafish maintained in standard conditions.</p></list-item><list-item><p><bold>Group II (GAL):</bold> Treated with galantamine (GAL, 1 mg/L), used as a positive control in behavioral and biochemical assessments.</p></list-item><list-item><p><bold>Groups III&#8211;V (FVEO):</bold> Treated with FVEO at 25, 150, and 300 &#181;L/L, respectively.</p></list-item><list-item><p><bold>Group VI (SCOP):</bold> Treated with scopolamine (SCOP, 100 &#181;M) to induce a dementia-like phenotype.</p></list-item><list-item><p><bold>Group VII (SCOP + GAL):</bold> Treated with SCOP (100 &#181;M), followed by GAL (1 mg/L).</p></list-item><list-item><p><bold>Groups VIII&#8211;X (SCOP + FVEO):</bold> Treated with SCOP (100 &#181;M), followed by FVEO at 25, 150, or 300 &#181;L/L, respectively.</p></list-item></list></p><p>GAL (1 mg/L) was administered by immersion in a 500 mL cylindrical beaker for 3 min before behavioral testing. In Group VII, GAL was administered for 3 min following SCOP treatment. FVEO was chronically administered to Groups III&#8211;V and VIII&#8211;X at concentrations of 25, 150, or 300 &#181;L/L dissolved in 1% Tween 80, with fresh solution provided during daily water changes. Dosages were selected based on previous findings [<xref rid="B78-molecules-30-02858" ref-type="bibr">78</xref>]. The dementia-like state was induced using SCOP (100 &#181;M, immersion for 30 min) before behavioral assessments, following protocols validated in previous studies [<xref rid="B48-molecules-30-02858" ref-type="bibr">48</xref>,<xref rid="B78-molecules-30-02858" ref-type="bibr">78</xref>]. This rigorously controlled protocol was designed to comprehensively evaluate the neuropharmacological and behavioral effects of FVEO in a validated zebrafish model of cognitive impairment.</p></sec><sec id="sec3dot6-molecules-30-02858"><title>3.6. Behavioral Analysis</title><p>To assess the effects of FVEO on zebrafish behavior, an advanced video tracking method was employed. Behavioral sessions were recorded using a Logitech HD Webcam C922 Pro Stream (Logitech, Lausanne, Switzerland). The recorded videos were subsequently analyzed using ANY-maze<sup>&#174;</sup> software version 7.48 (Stoelting Co., Wood Dale, IL, USA), which enabled automated and accurate quantification of behavioral parameters.</p><sec id="sec3dot6dot1-molecules-30-02858"><title>3.6.1. Novel Tank Diving Test (NTT)</title><p>The NTT, a validated method for assessing anxiety-like behavior in zebrafish, was conducted as described by Cachat et al. [<xref rid="B79-molecules-30-02858" ref-type="bibr">79</xref>]. The test apparatus consisted of a transparent trapezoidal tank (1.5 L; dimensions: 15.2 &#215; 27.9 &#215; 7.1 cm) divided equally into two horizontal zones: top and bottom. Following FVEO treatment, each fish was individually transferred to the testing tank, and behavior was recorded over a 6 min session.</p><p>Anxiety-like behavior was evaluated based on the following parameters: number of entries into the top zone, time spent in the top zone (s), and latency to first entry into the top zone (s). In addition, locomotor activity was assessed using distance traveled in the top zone (m), freezing duration (s), and average swimming velocity (m/s). These metrics provided comprehensive insights into both anxiety-related responses and general locomotor behavior, thereby facilitating a nuanced evaluation of FVEO&#8217;s neuropharmacological effects.</p></sec><sec id="sec3dot6dot2-molecules-30-02858"><title>3.6.2. Y-Maze Test</title><p>The Y-maze test was employed to assess the effects of FVEO on spatial memory and response to novelty in zebrafish, following the protocol described by Cognato et al. [<xref rid="B80-molecules-30-02858" ref-type="bibr">80</xref>].</p><p>The apparatus consisted of a Y-shaped glass tank (3 L; arm dimensions: 25 &#215; 8 &#215; 15 cm), with distinct geometric shapes (squares, circles, triangles) affixed to the outer walls of each arm for spatial orientation. The three arms were designated as follows: (i) the start arm, from which the fish began each trial (always open); (ii) the novel arm, which was closed during the first trial and opened during the second; and (iii) the other arm, which remained open throughout both trials. The central intersection of the maze (neutral zone) was excluded from behavioral analysis.</p><p>The test consisted of two trials separated by a 1 h inter-trial interval. During the first trial (training phase, 5 min), zebrafish were allowed to explore only the start and other arms, with the novel arm blocked. In the second trial (test phase, 5 min), all three arms were accessible to evaluate exploratory behavior and memory performance. The following behavioral parameters were measured: total distance traveled (m), spontaneous alternation (%), turn angle (&#176;), and time spent in the novel arm (s). These variables were used to assess spatial memory, locomotion, and response to novelty following FVEO treatment.</p></sec><sec id="sec3dot6dot3-molecules-30-02858"><title>3.6.3. Novel Object Recognition (NOR) Test</title><p>The NOR test was used to evaluate the effects of FVEO on recognition memory in zebrafish, following the protocol described by Stefanello et al. [<xref rid="B81-molecules-30-02858" ref-type="bibr">81</xref>]. The experimental apparatus consisted of a 20 L glass tank (30 &#215; 30 &#215; 30 cm) filled with 6 cm of water.</p><p>Before testing, zebrafish underwent a habituation phase in which each animal was exposed to the empty tank for 5 min, twice daily (with a 5 h interval between sessions), over three consecutive days. On the fourth day, the training phase was conducted, during which each fish was individually exposed to two identical red cubes (familiar objects) placed in the tank for 10 min. Following a 1 h retention interval, the test phase was performed: one red cube (familiar object, F) was replaced with a green cube (novel object, N), and the fish were allowed to explore both objects freely for 10 min.</p><p>The behavioral parameters evaluated included the time spent exploring each object (s) and the percentage of preference for the novel object. The preference percentage was calculated using the formula: [Time exploring novel object/(Time exploring familiar + novel object)] &#215; 100. This test allowed for the assessment of recognition memory and novelty discrimination following FVEO treatment.</p></sec></sec><sec id="sec3dot7-molecules-30-02858"><title>3.7. Biochemical Parameters Assay</title><p>At the end of the behavioral testing, zebrafish were individually transferred to glass containers containing ice-cold water (2&#8211;4 &#176;C) for 10 min to induce anesthesia. Euthanasia was then performed via rapid decapitation, following protocols previously described by our group [<xref rid="B78-molecules-30-02858" ref-type="bibr">78</xref>]. Whole brains were immediately extracted, individually weighed (approximately 3&#8211;6 mg), and transferred to 0.5 mL microcentrifuge tubes. Samples were stored at &#8722;20 &#176;C until further processing.</p><p>On the following day, brain samples from each experimental group were pooled and homogenized in cold phosphate buffer (0.1 M potassium phosphate, pH 7.4, containing 1.15% KCl) at a 1:10 (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) ratio. Homogenization was performed using a ball mill homogenizer (Mikro-Dismembrator U; Sartorius, NY, USA). The resulting homogenates were centrifuged at 14,000 rpm for 15 min at 4 &#176;C. The supernatants were collected and used for subsequent biochemical assays.</p><p>To comprehensively evaluate the neuroprotective and antioxidant effects of FVEO on zebrafish, a suite of biochemical markers was assessed in brain tissue homogenates collected post-behavioral testing. These analyses targeted cholinergic function, oxidative damage, and redox homeostasis.</p><p>Total protein content was determined using the bicinchoninic acid (BCA) assay kit (Cat. No. B9643, Sigma-Aldrich, Darmstadt, Germany), and was used to normalize all enzymatic activities and biomarker concentrations.</p><p>AChE activity, an index of cholinergic function, was measured spectrophotometrically using Ellman&#8217;s method [<xref rid="B82-molecules-30-02858" ref-type="bibr">82</xref>]. The reaction mixture (final volume: 1.5 mL) contained acetylthiocholine iodide (Cat. EC 3.1.1.7) and 5,5&#8242;-dithiobis(2-nitrobenzoic acid) (DTNB), both from Sigma-Aldrich. Samples were incubated at 37 &#176;C for 15 min, and absorbance was recorded at 412 nm. AChE activity was expressed as nmol substrate hydrolyzed/min/mg protein.</p><p>SOD (EC 1.15.1.1) activity was determined by measuring the inhibition of nitro blue tetrazolium (NBT) photoreduction in the presence of riboflavin (Sigma-Aldrich, Germany) under fluorescent light [<xref rid="B83-molecules-30-02858" ref-type="bibr">83</xref>]. The reaction mixture included 0.067 M potassium phosphate buffer (pH 7.8), 0.1 M disodium EDTA (Carl Roth, Germany), 1.5 mM NBT (AppliChem, Darmstadt, Germany), and 0.12 mM riboflavin, to which 50 &#181;L of enzymatic extract was added for the test samples, while control samples contained no enzyme extract. The reaction mixtures were exposed to fluorescent light for 30 min at 25 &#176;C, followed by spectrophotometric reading at 560 nm using a Beckman Coulter DU 730 Life Science UV-VIS spectrophotometer (Brea, CA, USA). SOD activity was expressed as units per milligram of protein (U/mg protein), where one unit represents the amount of enzyme required to produce 50% inhibition of NBT reduction.</p><p>CAT (EC 1.11.1.6) activity was assessed using a modified Sinha method [<xref rid="B84-molecules-30-02858" ref-type="bibr">84</xref>] based on a chromogenic reaction with potassium dichromate and glacial acetic acid. A 0.1 M phosphate buffer (pH 7.4, with 1.15% KCl) served as the reaction medium. Hydrogen peroxide substrate solutions (0.16 M and 0.08 M) were freshly prepared in this buffer. Incubations were performed in a Thermomixer F1.5 (Eppendorf, Hamburg, Germany), and absorbance of the chromic acetate product was measured at 570 nm using a Beckman Coulter DU 730 UV-VIS spectrophotometer.</p><p>GPX (EC 1.11.1.9) activity was determined colorimetrically [<xref rid="B85-molecules-30-02858" ref-type="bibr">85</xref>] by measuring the oxidation of reduced glutathione (GSH, Sigma-Aldrich, Germany) in the presence of hydrogen peroxide. The reaction mixture contained 0.25 M sodium phosphate buffer (pH 7.4), 25 mM EDTA, 0.4 M sodium azide, and 78 &#181;L of enzyme extract, incubated for 10 min at 37 &#176;C. The reaction was initiated by adding 50 mM GSH and 50 mM H<sub>2</sub>O<sub>2</sub>, followed by another 10 min incubation. The reaction was stopped with 7% metaphosphoric acid, centrifuged, and the supernatant was reacted with 0.3 M Na<sub>2</sub>HPO<sub>4</sub> and DTNB. Absorbance was measured at 412 nm, and enzyme activity was expressed as &#181;g GSH oxidized per mg protein.</p><p>GSH levels [<xref rid="B86-molecules-30-02858" ref-type="bibr">86</xref>] were assessed using the DTNB-based method. Homogenates were deproteinized, neutralized, and incubated with DTNB. The yellow-colored complex was measured at 412 nm (final volume: 1.0 mL, 25 &#176;C, 5 min). Results were reported as &#181;mol GSH/mg protein.</p><p>Lipid peroxidation was estimated via MDA quantification using the thiobarbituric acid reactive substances (TBARS) assay [<xref rid="B87-molecules-30-02858" ref-type="bibr">87</xref>]. Brain homogenates were incubated with thiobarbituric acid (TBA, Sigma-Aldrich) and perchloric acid (Merck, Darmstadt, Germany) in 1.5 mL reaction volume at 95 &#176;C for 60 min. The MDA&#8211;TBA complex was measured at 532 nm and expressed as nmol MDA/mg protein.</p><p>Protein carbonyls were measured by precipitating 1 mg protein with 20% TCA, then reacting the pellet with 0.2% DNPH (Sigma-Aldrich) in 2N HCl for 1 h at room temperature [<xref rid="B88-molecules-30-02858" ref-type="bibr">88</xref>]. After a second TCA precipitation and washing with ethanol/ethyl acetate (1:1), the pellet was dissolved in 6 M guanidine hydrochloride in phosphate buffer. Absorbance was read at 370 nm the next day, and results expressed as nmol DNPH/mg protein.</p><p>All reagents were of analytical grade and used according to manufacturer protocols.</p></sec><sec id="sec3dot8-molecules-30-02858"><title>3.8. Statistical Analysis</title><p>All data are presented as mean &#177; standard error of the mean (SEM) to reflect central tendency and variability. Statistical comparisons between experimental groups were conducted using one-way analysis of variance (ANOVA), followed by Tukey&#8217;s post hoc test for multiple comparisons, with treatment as the independent variable. Statistical significance was set at <italic toggle="yes">p</italic> &lt; 0.05.</p><p>Analyses were performed using GraphPad Prism version 9.4 (GraphPad Software, Inc., San Diego, CA, USA). In addition, Pearson&#8217;s correlation coefficient (r) was used to explore potential relationships between behavioral parameters, enzymatic activity levels, and lipid peroxidation (MDA), offering insight into possible interdependencies within the biological response to FVEO treatment.</p></sec></sec><sec sec-type="conclusions" id="sec4-molecules-30-02858"><title>4. Conclusions</title><p>The results of this study demonstrate that FVEO, at concentrations of 25, 150, and 300 &#181;L/L, exerts significant neuroprotective effects in a zebrafish model of cognitive impairment and anxiety. Notably, the lowest concentration (25 &#181;L/L) showed the most pronounced behavioral improvements in cognitive and anxiety-related parameters, as assessed by the NTT, Y-maze, and NOR test.</p><p>FVEO effectively counteracted SCOP-induced oxidative stress in the brain, as evidenced by increased activity of antioxidant enzymes (SOD, CAT, and GPX), restoration of GSH levels, and reduction in protein carbonylation and lipid peroxidation (MDA). Furthermore, FVEO significantly inhibited AChE activity, supporting its role in enhancing cholinergic function and cognitive performance.</p><p>In silico ADMET analysis revealed favorable pharmacokinetic profiles for the five major FVEO compounds, including high absorption, efficient BBB and CNS permeability, and broad systemic distribution. Importantly, none of the compounds exhibited predicted hepatotoxicity, although a potential for epithelial tissue irritation was identified.</p><p>Together, these findings suggest that FVEO improves memory and anxiety-like behavior through dual modulation of the cholinergic system and oxidative balance in the brain. The results highlight the potential of FVEO as a natural therapeutic candidate for managing cognitive disorders and anxiety, offering a foundation for future studies on the role of essential oils in neuropharmacology.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.H., I.B. and R.S.B.; methodology, I.B., R.S.B., E.T.-C., L.H. and G.D.; software, I.B. and R.S.B.; investigation, I.B., R.S.B., E.T.-C. and G.D.; resources, L.H. and G.D.; writing&#8212;original draft preparation, I.B., G.D. and L.H.; writing&#8212;review and editing, I.B. and L.H.; funding acquisition, L.H., I.B. and R.S.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Animal Ethics Committee of the Faculty of Biology, Alexandru Ioan Cuza University of Iasi, Romania (Project approval no. 370/4 February 2022).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data is contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-30-02858"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.B.</given-names></name><name name-style="western"><surname>de Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van der Flier</surname><given-names>W.M.</given-names></name></person-group><article-title>Alzheimer&#8217;s Disease</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01124-1</pub-id><pub-id pub-id-type="pmid">26921134</pub-id></element-citation></ref><ref id="B2-molecules-30-02858"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graff-Radford</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>K.X.X.</given-names></name><name name-style="western"><surname>Apostolova</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Bouwman</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>M.E.</given-names></name></person-group><article-title>New Insights into Atypical Alzheimer&#8217;s Disease in the Era of Biomarkers</article-title><source>Lancet Neurol.</source><year>2021</year><volume>20</volume><fpage>222</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30440-3</pub-id><pub-id pub-id-type="pmid">33609479</pub-id><pub-id pub-id-type="pmcid">PMC8056394</pub-id></element-citation></ref><ref id="B3-molecules-30-02858"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mesulam</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cuello</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Giacobini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grossberg</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Khachaturian</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Vergallo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavedo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>The Cholinergic System in the Pathophysiology and Treatment of Alzheimer&#8217;s Disease</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>1917</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1093/brain/awy132</pub-id><pub-id pub-id-type="pmid">29850777</pub-id><pub-id pub-id-type="pmcid">PMC6022632</pub-id></element-citation></ref><ref id="B4-molecules-30-02858"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.F.</given-names></name></person-group><article-title>Role of Cholinergic Signaling in Alzheimer&#8217;s Disease</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1816</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27061816</pub-id><pub-id pub-id-type="pmid">35335180</pub-id><pub-id pub-id-type="pmcid">PMC8949236</pub-id></element-citation></ref><ref id="B5-molecules-30-02858"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekdash</surname><given-names>R.A.</given-names></name></person-group><article-title>The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer&#8217;s Disease</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1273</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22031273</pub-id><pub-id pub-id-type="pmid">33525357</pub-id><pub-id pub-id-type="pmcid">PMC7865740</pub-id></element-citation></ref><ref id="B6-molecules-30-02858"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Noroozi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>A.</given-names></name></person-group><article-title>Enlargement of Early Endosomes and Traffic Jam in Basal Forebrain Cholinergic Neurons in Alzheimer&#8217;s Disease</article-title><source>Handb. Clin. Neurol.</source><year>2021</year><volume>179</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-819975-6.00011-X</pub-id><pub-id pub-id-type="pmid">34225963</pub-id></element-citation></ref><ref id="B7-molecules-30-02858"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zammit</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>West</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Christian</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>A.</given-names></name></person-group><article-title>Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer&#8217;s Disease</article-title><source>Front. Aging Neurosci.</source><year>2021</year><volume>13</volume><fpage>703876</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2021.703876</pub-id><pub-id pub-id-type="pmid">34322015</pub-id><pub-id pub-id-type="pmcid">PMC8311593</pub-id></element-citation></ref><ref id="B8-molecules-30-02858"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>T.</given-names></name></person-group><article-title>Current Drug Treatments in Alzheimer&#8217;s Disease</article-title><source>Highlights Sci. Eng. Technol.</source><year>2023</year><volume>36</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.54097/hset.v36i.5691</pub-id></element-citation></ref><ref id="B9-molecules-30-02858"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peitzika</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pontiki</surname><given-names>E.</given-names></name></person-group><article-title>A Review on Recent Approaches on Molecular Docking Studies of Novel Compounds Targeting Acetylcholinesterase in Alzheimer Disease</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>1084</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28031084</pub-id><pub-id pub-id-type="pmid">36770750</pub-id><pub-id pub-id-type="pmcid">PMC9921523</pub-id></element-citation></ref><ref id="B10-molecules-30-02858"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandelshein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bloemer</surname><given-names>J.</given-names></name></person-group><article-title>Side Effects of Drugs Used in the Treatment of Alzheimer&#8217;s Disease</article-title><source>Side Eff. Drugs Annu.</source><year>2022</year><volume>44</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/BS.SEDA.2022.07.003</pub-id></element-citation></ref><ref id="B11-molecules-30-02858"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilie</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Stefaniu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Handaric</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dascalescu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivascu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alexa</surname><given-names>I.D.</given-names></name></person-group><article-title>Adverse Effects Of Cholinesterase Inhibitors In The Elderly Patient With Myasthenia Gravis. Case Reports</article-title><source>Med.-Surg. J.</source><year>2018</year><volume>122</volume><fpage>314</fpage><lpage>317</lpage></element-citation></ref><ref id="B12-molecules-30-02858"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blokland</surname><given-names>A.</given-names></name></person-group><article-title>Cholinergic Models of Memory Impairment in Animals and Man: Scopolamine vs. Biperiden</article-title><source>Behav. Pharmacol.</source><year>2022</year><volume>33</volume><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1097/FBP.0000000000000670</pub-id><pub-id pub-id-type="pmid">35621168</pub-id></element-citation></ref><ref id="B13-molecules-30-02858"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Yeong</surname><given-names>K.Y.</given-names></name></person-group><article-title>Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer&#8217;s Disease</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2020</year><volume>19</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.2174/1871527319666200214104331</pub-id><pub-id pub-id-type="pmid">32056532</pub-id></element-citation></ref><ref id="B14-molecules-30-02858"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Sheu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.H.</given-names></name></person-group><article-title>The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease</article-title><source>Mayo Clin. Proc.</source><year>2021</year><volume>96</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.05.048</pub-id><pub-id pub-id-type="pmid">33549256</pub-id></element-citation></ref><ref id="B15-molecules-30-02858"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hern&#225;ndez-Rodr&#237;guez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arciniega-Mart&#237;nez</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mar&#237;n</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Correa-Basurto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rosales-Hern&#225;ndez</surname><given-names>M.C.</given-names></name></person-group><article-title>Chronic Administration of Scopolamine Increased GSK3&#946;P9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats</article-title><source>Mol. Neurobiol.</source><year>2020</year><volume>57</volume><fpage>3979</fpage><lpage>3988</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02009-x</pub-id><pub-id pub-id-type="pmid">32638218</pub-id></element-citation></ref><ref id="B16-molecules-30-02858"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kishore</surname><given-names>N.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.K.</given-names></name></person-group><article-title>Foeniculum Vulgare Mill: Flavoring, Pharmacological, Phytochemical, and Folklore Aspects</article-title><source>Medicinal Plants</source><publisher-name>Apple Academic Press</publisher-name><publisher-loc>Palm Bay, FL, USA</publisher-loc><year>2022</year><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1201/9781003277408-4</pub-id></element-citation></ref><ref id="B17-molecules-30-02858"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crescenzi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>D&#8217;Urso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Piacente</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montoro</surname><given-names>P.</given-names></name></person-group><article-title>UPLC-ESI-QTRAP-MS/MS Analysis to Quantify Bioactive Compounds in Fennel (<italic toggle="yes">Foeniculum Vulgare</italic> Mill.) Waste with Potential Anti-Inflammatory Activity</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><elocation-id>701</elocation-id><pub-id pub-id-type="doi">10.3390/metabo12080701</pub-id><pub-id pub-id-type="pmid">36005573</pub-id><pub-id pub-id-type="pmcid">PMC9414302</pub-id></element-citation></ref><ref id="B18-molecules-30-02858"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amiza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rauf</surname><given-names>A.</given-names></name><name name-style="western"><surname>ud Din</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sehar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khawaja</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Haroon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>R.</given-names></name></person-group><article-title>A Concise Review on Toxicity and Pharmacological Aspects of <italic toggle="yes">Foeniculum Vulgare</italic> with Emphasis on Anti-Cancer Potential</article-title><source>Asian J. Res. Pharm. Sci.</source><year>2022</year><volume>12</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.52711/2231-5659.2022.00013</pub-id></element-citation></ref><ref id="B19-molecules-30-02858"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debnath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medicine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Khoshnevisan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alipanah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baharifar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Osanloo</surname><given-names>M.</given-names></name></person-group><article-title>Foeniculum Vulgare from Spice to Pharma: Recent Advances in Its Medicinal Value, Bioactivities and Perspectives</article-title><source>Tradit. Integr. Med.</source><year>2023</year><volume>8</volume><fpage>217</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.18502/tim.v8i2.13087</pub-id></element-citation></ref><ref id="B20-molecules-30-02858"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherbal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouabdallah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benhalla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hireche</surname><given-names>S.</given-names></name><name name-style="western"><surname>Desdous</surname><given-names>R.</given-names></name></person-group><article-title>Phytochemical Screening, Phenolic Content, and Anti-Inflammatory Effect of Foeniculum Vulgare Seed Extract</article-title><source>Prev. Nutr. Food Sci.</source><year>2023</year><volume>28</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.3746/pnf.2023.28.2.141</pub-id><pub-id pub-id-type="pmid">37416792</pub-id><pub-id pub-id-type="pmcid">PMC10321444</pub-id></element-citation></ref><ref id="B21-molecules-30-02858"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sayyed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mali</surname><given-names>R.</given-names></name></person-group><article-title>Medicinal Traits of the Phenolic Compound from Foeniculum Vulgare for Oligomenorrhea</article-title><source>Chem. Proc.</source><year>2022</year><volume>12</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3390/ECSOC-26-13724</pub-id></element-citation></ref><ref id="B22-molecules-30-02858"><label>22.</label><element-citation publication-type="webpage"><article-title>SwissADME</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.swissadme.ch/" ext-link-type="uri">http://www.swissadme.ch/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-13">(accessed on 13 October 2023)</date-in-citation></element-citation></ref><ref id="B23-molecules-30-02858"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>D.E.V.</given-names></name><name name-style="western"><surname>Blundell</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ascher</surname><given-names>D.B.</given-names></name></person-group><article-title>PkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>4066</fpage><lpage>4072</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id><pub-id pub-id-type="pmid">25860834</pub-id><pub-id pub-id-type="pmcid">PMC4434528</pub-id></element-citation></ref><ref id="B24-molecules-30-02858"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Waterbeemd</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>E.</given-names></name></person-group><article-title>ADMET in Silico Modelling: Towards Prediction Paradise?</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>192</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/nrd1032</pub-id><pub-id pub-id-type="pmid">12612645</pub-id></element-citation></ref><ref id="B25-molecules-30-02858"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cioanca</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hancianu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mircea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trifan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hritcu</surname><given-names>L.</given-names></name></person-group><article-title>Essential Oils from Apiaceae as Valuable Resources in Neurological Disorders: Foeniculi Vulgare Aetheroleum</article-title><source>Ind. Crops Prod.</source><year>2016</year><volume>88</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2016.02.064</pub-id></element-citation></ref><ref id="B26-molecules-30-02858"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mare&#351;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Udrea</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>&#350;u&#355;an</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Avram</surname><given-names>S.</given-names></name></person-group><article-title>Bioinformatics Tools for the Analysis of Active Compounds Identified in Ranunculaceae Species</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>842</elocation-id><pub-id pub-id-type="doi">10.3390/ph16060842</pub-id><pub-id pub-id-type="pmid">37375790</pub-id><pub-id pub-id-type="pmcid">PMC10303079</pub-id></element-citation></ref><ref id="B27-molecules-30-02858"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Uzairu</surname><given-names>A.</given-names></name></person-group><article-title>2D-QSAR, Molecular Docking, Drug-Likeness, and ADMET/Pharmacokinetic Predictions of Some Non-Small Cell Lung Cancer Therapeutic Agents</article-title><source>J. Taibah Univ. Med. Sci.</source><year>2023</year><volume>18</volume><fpage>295</fpage><pub-id pub-id-type="doi">10.1016/j.jtumed.2022.09.002</pub-id><pub-id pub-id-type="pmid">36817217</pub-id><pub-id pub-id-type="pmcid">PMC9926115</pub-id></element-citation></ref><ref id="B28-molecules-30-02858"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.S.</given-names></name></person-group><article-title>Admetlab: A Platform for Systematic ADMET Evaluation Based on a Comprehensively Collected ADMET Database</article-title><source>J. Cheminform.</source><year>2018</year><volume>10</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0283-x</pub-id><pub-id pub-id-type="pmid">29943074</pub-id><pub-id pub-id-type="pmcid">PMC6020094</pub-id></element-citation></ref><ref id="B29-molecules-30-02858"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dominy</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</article-title><source>Adv. Drug Deliv. Rev.</source><year>1997</year><volume>23</volume><fpage>3</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(96)00423-1</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B30-molecules-30-02858"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bickerton</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Paolini</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Besnard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muresan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>A.L.</given-names></name></person-group><article-title>Quantifying the Chemical Beauty of Drugs</article-title><source>Nat. Chem.</source><year>2012</year><volume>4</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nchem.1243</pub-id><pub-id pub-id-type="pmid">22270643</pub-id><pub-id pub-id-type="pmcid">PMC3524573</pub-id></element-citation></ref><ref id="B31-molecules-30-02858"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghose</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Viswanadhan</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Wendoloski</surname><given-names>J.J.</given-names></name></person-group><article-title>A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases</article-title><source>J. Comb. Chem.</source><year>1999</year><volume>1</volume><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1021/cc9800071</pub-id><pub-id pub-id-type="pmid">10746014</pub-id></element-citation></ref><ref id="B32-molecules-30-02858"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Merz</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J.J.</given-names></name></person-group><article-title>Prediction of Drug Absorption Using Multivariate Statistics</article-title><source>J. Med. Chem.</source><year>2000</year><volume>43</volume><fpage>3867</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.1021/jm000292e</pub-id><pub-id pub-id-type="pmid">11052792</pub-id></element-citation></ref><ref id="B33-molecules-30-02858"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furey</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Drevets</surname><given-names>W.C.</given-names></name></person-group><article-title>Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men</article-title><source>Neuropsychopharmacology</source><year>2010</year><volume>35</volume><fpage>2479</fpage><pub-id pub-id-type="doi">10.1038/npp.2010.131</pub-id><pub-id pub-id-type="pmid">20736989</pub-id><pub-id pub-id-type="pmcid">PMC3055321</pub-id></element-citation></ref><ref id="B34-molecules-30-02858"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M.T.</given-names></name></person-group><article-title>Anxiolytic Effects of Environmental Enrichment Attenuate Sex-Related Anxiogenic Effects of Scopolamine in Rats</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2013</year><volume>40</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.10.009</pub-id><pub-id pub-id-type="pmid">23085072</pub-id></element-citation></ref><ref id="B35-molecules-30-02858"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Morrill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gallup</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Healey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pitman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schalomon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Digweed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tresguerres</surname><given-names>M.</given-names></name></person-group><article-title>Establishing Zebrafish as a Model to Study the Anxiolytic Effects of Scopolamine</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>15081</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-15374-w</pub-id><pub-id pub-id-type="pmid">29118373</pub-id><pub-id pub-id-type="pmcid">PMC5678162</pub-id></element-citation></ref><ref id="B36-molecules-30-02858"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.J.</given-names></name></person-group><article-title>Scopolamine-Induced Learning Impairment Reversed by Physostigmine in Zebrafish</article-title><source>Neurosci. Res.</source><year>2010</year><volume>67</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2010.03.003</pub-id><pub-id pub-id-type="pmid">20298728</pub-id></element-citation></ref><ref id="B37-molecules-30-02858"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singsai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ladpala</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dangja</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boonchuen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jaikhamfu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fakthong</surname><given-names>P.</given-names></name></person-group><article-title>Effect of Streblus Asper Leaf Extract on Scopolamine-Induced Memory Deficits in Zebrafish: The Model of Alzheimer&#8217;s Disease</article-title><source>Adv. Pharmacol. Pharm. Sci.</source><year>2021</year><volume>2021</volume><fpage>6666726</fpage><pub-id pub-id-type="doi">10.1155/2021/6666726</pub-id><pub-id pub-id-type="pmid">33987539</pub-id><pub-id pub-id-type="pmcid">PMC8093034</pub-id></element-citation></ref><ref id="B38-molecules-30-02858"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richetti</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>M.</given-names></name><name name-style="western"><surname>Capiotti</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Piato</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bogo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Vianna</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bonan</surname><given-names>C.D.</given-names></name></person-group><article-title>Quercetin and Rutin Prevent Scopolamine-Induced Memory Impairment in Zebrafish</article-title><source>Behav. Brain Res.</source><year>2011</year><volume>217</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2010.09.027</pub-id><pub-id pub-id-type="pmid">20888863</pub-id></element-citation></ref><ref id="B39-molecules-30-02858"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amoah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Atawuchugi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jibira</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tandoh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ossei</surname><given-names>P.P.S.</given-names></name><name name-style="western"><surname>Sam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ainooson</surname><given-names>G.</given-names></name></person-group><article-title>Lantana Camara Leaf Extract Ameliorates Memory Deficit and the Neuroinflammation Associated with Scopolamine-Induced Alzheimer&#8217;s-like Cognitive Impairment in Zebrafish and Mice</article-title><source>Pharm. Biol.</source><year>2023</year><volume>61</volume><fpage>825</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1080/13880209.2023.2209130</pub-id><pub-id pub-id-type="pmid">37212299</pub-id><pub-id pub-id-type="pmcid">PMC10208155</pub-id></element-citation></ref><ref id="B40-molecules-30-02858"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name></person-group><article-title>Characterization and Exploration of Potential Neuroprotective Peptides in Walnut (Juglans Regia) Protein Hydrolysate against Cholinergic System Damage and Oxidative Stress in Scopolamine-Induced Cognitive and Memory Impairment Mice and Zebrafish</article-title><source>J. Agric. Food Chem.</source><year>2021</year><volume>69</volume><fpage>2773</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.0c07798</pub-id><pub-id pub-id-type="pmid">33645974</pub-id></element-citation></ref><ref id="B41-molecules-30-02858"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarado-Garc&#237;a</surname><given-names>P.A.A.</given-names></name><name name-style="western"><surname>Soto-Vasquez</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rosales-Cerquin</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Rodrigo-Villanueva</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Jara-Aguilar</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Tuesta-Collantes</surname><given-names>L.</given-names></name></person-group><article-title>Anxiolytic and Antidepressant-like Effects of <italic toggle="yes">Foeniculum Vulgare</italic> Essential Oil</article-title><source>Pharmacogn. J.</source><year>2022</year><volume>14</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.5530/pj.2022.14.54</pub-id></element-citation></ref><ref id="B42-molecules-30-02858"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asle-Rousta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahnema</surname><given-names>M.</given-names></name></person-group><article-title>Protective Effect of Fennel, and Its Major Component Trans-Anethole against Social Isolation Induced Behavioral Deficits in Rats</article-title><source>Physiol. Int.</source><year>2020</year><volume>107</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1556/2060.2020.00012</pub-id><pub-id pub-id-type="pmid">32491286</pub-id></element-citation></ref><ref id="B43-molecules-30-02858"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Haghighat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khazali</surname><given-names>H.</given-names></name></person-group><article-title>The Effects of Trans-Anethole on the Hypothalamic CGRP and CRH Gene Expression in Rat Model of Stress</article-title><source>Arch. Adv. Biosci.</source><year>2023</year><volume>14</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.22037/AAB.V14I1.41158</pub-id></element-citation></ref><ref id="B44-molecules-30-02858"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volgin</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Yakovlev</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Demin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Alekseeva</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kalueff</surname><given-names>A.V.</given-names></name></person-group><article-title>Acute Behavioral Effects of Deliriant Hallucinogens Atropine and Scopolamine in Adult Zebrafish</article-title><source>Behav. Brain Res.</source><year>2019</year><volume>359</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2018.10.033</pub-id><pub-id pub-id-type="pmid">30366034</pub-id></element-citation></ref><ref id="B45-molecules-30-02858"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pande</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>C.</given-names></name></person-group><article-title>Effect of Lactobacillus Rhamnosus and Diclofenac with Curcumin for Neuronal Restoration and Repair Against Scopolamine Induced Dementia in Zebrafish (<italic toggle="yes">Danio Rerio</italic>)</article-title><source>Curr. Enzym. Inhib.</source><year>2023</year><volume>19</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.2174/1573408019666230508155702</pub-id></element-citation></ref><ref id="B46-molecules-30-02858"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delaram</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Shahrbanoo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Maryam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Farhad</surname><given-names>V.</given-names></name></person-group><article-title>Effect of Fennel Extract on the Improvement of Memory Disorders in Beta Amyloid Alzheimer Model of Male Wistar Rats</article-title><source>J. Ilam Univ. Med. Sci.</source><year>2019</year><volume>27</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.29252/SJIMU.27.1.1</pub-id></element-citation></ref><ref id="B47-molecules-30-02858"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ali Shah</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zahid</surname><given-names>S.</given-names></name></person-group><article-title>Neuroprotective Effects of <italic toggle="yes">Foeniculum Vulgare</italic> Seeds Extract on Lead-Induced Neurotoxicity in Mice Brain</article-title><source>Drug Chem. Toxicol.</source><year>2018</year><volume>41</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1080/01480545.2018.1459669</pub-id><pub-id pub-id-type="pmid">29742941</pub-id></element-citation></ref><ref id="B48-molecules-30-02858"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Eldahshan</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Hritcu</surname><given-names>L.</given-names></name></person-group><article-title>Baicalein 5,6-Dimethyl Ether Prevents Memory Deficits in the Scopolamine Zebrafish Model by Regulating Cholinergic and Antioxidant Systems</article-title><source>Plants</source><year>2021</year><volume>10</volume><elocation-id>1245</elocation-id><pub-id pub-id-type="doi">10.3390/plants10061245</pub-id><pub-id pub-id-type="pmid">34207381</pub-id><pub-id pub-id-type="pmcid">PMC8233988</pub-id></element-citation></ref><ref id="B49-molecules-30-02858"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koppula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.</given-names></name></person-group><article-title><italic toggle="yes">Foeniculum Vulgare</italic> Mill (Umbelliferae) Attenuates Stress and Improves Memory in Wister Rats</article-title><source>Trop. J. Pharm. Res.</source><year>2013</year><volume>12</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v12i4.17</pub-id></element-citation></ref><ref id="B50-molecules-30-02858"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>W.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seol</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Min</surname><given-names>S.S.</given-names></name></person-group><article-title>Trans-Anethole Alleviates Trimethyltin Chloride-Induced Impairments in Long-Term Potentiation</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1422</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14071422</pub-id><pub-id pub-id-type="pmid">35890317</pub-id><pub-id pub-id-type="pmcid">PMC9320999</pub-id></element-citation></ref><ref id="B51-molecules-30-02858"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Beckers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Onur</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Dietlein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tittgemeyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kracht</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neumaier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Kukolja</surname><given-names>J.</given-names></name></person-group><article-title>Effect of Cholinergic Treatment Depends on Cholinergic Integrity in Early Alzheimer&#8217;s Disease</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>903</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1093/brain/awx356</pub-id><pub-id pub-id-type="pmid">29309600</pub-id></element-citation></ref><ref id="B52-molecules-30-02858"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Potkin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Enz</surname><given-names>A.</given-names></name></person-group><article-title>Targeting Acetylcholinesterase and Butyrylcholinesterase in Dementia</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2006</year><volume>9</volume><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1017/S1461145705005833</pub-id><pub-id pub-id-type="pmid">16083515</pub-id></element-citation></ref><ref id="B53-molecules-30-02858"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Baki</surname><given-names>A.A.S.</given-names></name><name name-style="western"><surname>Aboelhadid</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sokmen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Quraishy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>A.A.</given-names></name></person-group><article-title>Larvicidal and Pupicidal Activities of <italic toggle="yes">Foeniculum Vulgare</italic> Essential Oil, Trans-Anethole and Fenchone against House Fly <italic toggle="yes">Musca Domestica</italic> and Their Inhibitory Effect on Acetylcholinestrase</article-title><source>Entomol. Res.</source><year>2021</year><volume>51</volume><fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1111/1748-5967.12550</pub-id></element-citation></ref><ref id="B54-molecules-30-02858"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Parle</surname><given-names>M.</given-names></name></person-group><article-title>Cholinergic Basis of Memory-Strengthening Effect of <italic toggle="yes">Foeniculum Vulgare</italic> Linn</article-title><source>J. Med. Food</source><year>2006</year><volume>9</volume><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1089/jmf.2006.9.413</pub-id><pub-id pub-id-type="pmid">17004908</pub-id></element-citation></ref><ref id="B55-molecules-30-02858"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahriari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zibaee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sahebzadeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shamakhi</surname><given-names>L.</given-names></name></person-group><article-title>Effects of &#945;-Pinene, Trans-Anethole, and Thymol as the Essential Oil Constituents on Antioxidant System and Acetylcholine Esterase of <italic toggle="yes">Ephestia Kuehniella</italic> Zeller (Lepidoptera: Pyralidae)</article-title><source>Pestic. Biochem. Physiol.</source><year>2018</year><volume>150</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.pestbp.2018.06.015</pub-id><pub-id pub-id-type="pmid">30195386</pub-id></element-citation></ref><ref id="B56-molecules-30-02858"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rottkamp</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Nunomura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raina</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name></person-group><article-title>Oxidative Stress in Alzheimer&#8217;s Disease</article-title><source>Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.</source><year>2000</year><volume>1502</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/S0925-4439(00)00040-5</pub-id><pub-id pub-id-type="pmid">10899439</pub-id></element-citation></ref><ref id="B57-molecules-30-02858"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name></person-group><article-title>Oxidative Stress in Alzheimer&#8217;s Disease</article-title><source>Neurosci. Bull.</source><year>2014</year><volume>30</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1007/s12264-013-1423-y</pub-id><pub-id pub-id-type="pmid">24664866</pub-id><pub-id pub-id-type="pmcid">PMC5562667</pub-id></element-citation></ref><ref id="B58-molecules-30-02858"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.W.</given-names></name></person-group><article-title>Role of Oxidative Stress in Alzheimer&#8217;s Disease (Review)</article-title><source>Biomed. Rep.</source><year>2016</year><volume>4</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.3892/br.2016.630</pub-id><pub-id pub-id-type="pmid">27123241</pub-id><pub-id pub-id-type="pmcid">PMC4840676</pub-id></element-citation></ref><ref id="B59-molecules-30-02858"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.O.</given-names></name></person-group><article-title>Melatonin Rescue Oxidative Stress-Mediated Neuroinflammation/ Neurodegeneration and Memory Impairment in Scopolamine-Induced Amnesia Mice Model</article-title><source>J. Neuroimmune Pharmacol.</source><year>2019</year><volume>14</volume><fpage>278</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1007/s11481-018-9824-3</pub-id><pub-id pub-id-type="pmid">30478761</pub-id></element-citation></ref><ref id="B60-molecules-30-02858"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jaya Balan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kasi</surname><given-names>P.D.</given-names></name></person-group><article-title>Mitigation of Oxidative Stress with Dihydroactinidiolide, a Natural Product against Scopolamine-Induced Amnesia in Swiss Albino Mice</article-title><source>Neurotoxicology</source><year>2021</year><volume>86</volume><fpage>149</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2021.08.003</pub-id><pub-id pub-id-type="pmid">34371027</pub-id></element-citation></ref><ref id="B61-molecules-30-02858"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alghamdi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Abbasi</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alzarea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almalki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sayyed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Europinidin Attenuates Scopolamine-Induced Deficit Memory in Rats by Improving Neurobehavioral Activity, Inhibiting AChE Levels and BDNF Expression</article-title><source>Authorea</source><year>2023</year><pub-id pub-id-type="doi">10.22541/AU.168292805.53778198/V1</pub-id></element-citation></ref><ref id="B62-molecules-30-02858"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karthivashan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kweon</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>D.K.</given-names></name></person-group><article-title>Ameliorative Potential of Desalted Salicornia Europaea L. Extract in Multifaceted Alzheimer&#8217;s-like Scopolamine-Induced Amnesic Mice Model</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8826</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-25381-0</pub-id><pub-id pub-id-type="pmid">29740000</pub-id><pub-id pub-id-type="pmcid">PMC5940894</pub-id></element-citation></ref><ref id="B63-molecules-30-02858"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Ginsenoside Compound K Regulates Amyloid &#946; via the Nrf2/Keap1 Signaling Pathway in Mice with Scopolamine Hydrobromide-Induced Memory Impairments</article-title><source>J. Mol. Neurosci.</source><year>2019</year><volume>67</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s12031-018-1210-3</pub-id><pub-id pub-id-type="pmid">30535776</pub-id></element-citation></ref><ref id="B64-molecules-30-02858"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name></person-group><article-title>DL0410 Attenuates Oxidative Stress and Neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 Activation</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>86</volume><fpage>106729</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106729</pub-id><pub-id pub-id-type="pmid">32645628</pub-id></element-citation></ref><ref id="B65-molecules-30-02858"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>T.H.</given-names></name></person-group><article-title>Dietary <italic toggle="yes">Foeniculum Vulgare</italic> Mill Extract Attenuated UVB Irradiation-Induced Skin Photoaging by Activating of Nrf2 and Inhibiting MAPK Pathways</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><fpage>1273</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2016.06.008</pub-id><pub-id pub-id-type="pmid">27765346</pub-id></element-citation></ref><ref id="B66-molecules-30-02858"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>Trans-Anethole Ameliorates Intestinal Injury Through Activation of Nrf2 Signaling Pathway in Subclinical Necrotic Enteritis-Induced Broilers</article-title><source>Front. Vet. Sci.</source><year>2022</year><volume>9</volume><fpage>877066</fpage><pub-id pub-id-type="doi">10.3389/fvets.2022.877066</pub-id><pub-id pub-id-type="pmid">35518639</pub-id><pub-id pub-id-type="pmcid">PMC9062583</pub-id></element-citation></ref><ref id="B67-molecules-30-02858"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashemi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>S.</given-names></name></person-group><article-title>Alpha-Pinene Moderates Memory Impairment Induced by Kainic Acid via Improving the BDNF/TrkB/CREB Signaling Pathway in Rat Hippocampus</article-title><source>Front. Mol. Neurosci.</source><year>2023</year><volume>16</volume><fpage>1202232</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2023.1202232</pub-id><pub-id pub-id-type="pmid">37456525</pub-id><pub-id pub-id-type="pmcid">PMC10347414</pub-id></element-citation></ref><ref id="B68-molecules-30-02858"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Pancholi</surname><given-names>S.S.</given-names></name></person-group><article-title>Investigation of Antimutagenic Potential of <italic toggle="yes">Foeniculum Vulgare</italic> Essential Oil on Cyclophosphamide Induced Genotoxicity and Oxidative Stress in Mice</article-title><source>Drug Chem. Toxicol.</source><year>2013</year><volume>36</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.3109/01480545.2011.648328</pub-id><pub-id pub-id-type="pmid">22264205</pub-id></element-citation></ref><ref id="B69-molecules-30-02858"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barakat</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alkabeer</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Aljutaily</surname><given-names>T.</given-names></name><name name-style="western"><surname>Almujaydil</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Algheshairy</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Alhomaid</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Almutairi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A.</given-names></name></person-group><article-title>Phenolics and Volatile Compounds of Fennel (<italic toggle="yes">Foeniculum Vulgare</italic>) Seeds and Their Sprouts Prevent Oxidative DNA Damage and Ameliorates CCl4-Induced Hepatotoxicity and Oxidative Stress in Rats</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>2318</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11122318</pub-id><pub-id pub-id-type="pmid">36552526</pub-id><pub-id pub-id-type="pmcid">PMC9774655</pub-id></element-citation></ref><ref id="B70-molecules-30-02858"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Razzaq</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Shabbir</surname><given-names>A.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Foeniculum Vulgare</italic> (Fennel) Promotes Functional Recovery and Ameliorates Oxidative Stress Following a Lesion to the Sciatic Nerve in Mouse Model</article-title><source>J. Food Biochem.</source><year>2019</year><volume>43</volume><fpage>e12983</fpage><pub-id pub-id-type="doi">10.1111/jfbc.12983</pub-id><pub-id pub-id-type="pmid">31489666</pub-id></element-citation></ref><ref id="B71-molecules-30-02858"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Won</surname><given-names>K.J.</given-names></name></person-group><article-title>Sabinene Prevents Skeletal Muscle Atrophy by Inhibiting the MAPK&#8211;MuRF-1 Pathway in Rats</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>4955</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20194955</pub-id><pub-id pub-id-type="pmid">31597276</pub-id><pub-id pub-id-type="pmcid">PMC6801606</pub-id></element-citation></ref><ref id="B72-molecules-30-02858"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhingra</surname><given-names>D.</given-names></name></person-group><article-title>Sudha Antidepressant-Like Activity Of Trans-Anethole In Unstressed Mice And Stressed Mice</article-title><source>Asian J. Pharm. Clin. Res.</source><year>2019</year><volume>12</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.22159/ajpcr.2019.v12i12.35542</pub-id></element-citation></ref><ref id="B73-molecules-30-02858"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>H.A.A.H.</given-names></name><name name-style="western"><surname>Kandeil</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Khalaf</surname><given-names>M.M.</given-names></name></person-group><article-title>Neuroprotective Role of Camphor against Ciprofloxacin Induced Depression in Rats: Modulation of Nrf-2 and TLR4</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2021</year><volume>43</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1080/08923973.2021.1905658</pub-id><pub-id pub-id-type="pmid">34032546</pub-id></element-citation></ref><ref id="B74-molecules-30-02858"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chinnathambi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alahmadi</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name></person-group><article-title>D-Carvone Inhibit Cerebral Ischemia/Reperfusion Induced Inflammatory Response TLR4/NLRP3 Signaling Pathway</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>132</volume><fpage>110870</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110870</pub-id><pub-id pub-id-type="pmid">33080468</pub-id></element-citation></ref><ref id="B75-molecules-30-02858"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name></person-group><article-title>Ameliorative Effect of &#914;-pinene Targeting Mitochondrial Dysfunction and Oxidative Stress in Alzheimer&#8217;s Disease</article-title><source>Alzheimer&#8217;s Dement.</source><year>2023</year><volume>19</volume><fpage>e076020</fpage><pub-id pub-id-type="doi">10.1002/alz.076020</pub-id></element-citation></ref><ref id="B76-molecules-30-02858"><label>76.</label><element-citation publication-type="webpage"><article-title>Way2Drug-Main</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/PASSOnline/index.php" ext-link-type="uri">https://www.way2drug.com/PASSOnline/index.php</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-06">(accessed on 6 November 2023)</date-in-citation></element-citation></ref><ref id="B77-molecules-30-02858"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percie du Sert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hurst</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avey</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuthill</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Dirnagl</surname><given-names>U.</given-names></name><etal/></person-group><article-title>The ARRIVE Guidelines 2.0: Updated Guidelines for Reporting Animal Research</article-title><source>PLoS Biol.</source><year>2020</year><volume>18</volume><fpage>e3000410</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000410</pub-id><pub-id pub-id-type="pmid">32663219</pub-id><pub-id pub-id-type="pmcid">PMC7360023</pub-id></element-citation></ref><ref id="B78-molecules-30-02858"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Boiangiu</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Cioanca</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hancianu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dumitru</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hritcu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Birsan</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Todirascu-Ciornea</surname><given-names>E.</given-names></name></person-group><article-title>Direct Evidence for Using Coriandrum Sativum Var. Microcarpum Essential Oil to Ameliorate Scopolamine-Induced Memory Impairment and Brain Oxidative Stress in the Zebrafish Model</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><elocation-id>1534</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12081534</pub-id><pub-id pub-id-type="pmid">37627529</pub-id><pub-id pub-id-type="pmcid">PMC10451280</pub-id></element-citation></ref><ref id="B79-molecules-30-02858"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cachat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gaikwad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilder</surname><given-names>T.</given-names></name><name name-style="western"><surname>DiLeo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Utterback</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kalueff</surname><given-names>A.V.</given-names></name></person-group><article-title>Homebase Behavior of Zebrafish in Novelty-Based Paradigms</article-title><source>Behav. Process.</source><year>2010</year><volume>85</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.beproc.2010.07.009</pub-id><pub-id pub-id-type="pmid">20674703</pub-id></element-citation></ref><ref id="B80-molecules-30-02858"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cognato</surname><given-names>G.d.P.</given-names></name><name name-style="western"><surname>Bortolotto</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Blazina</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Christoff</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Lara</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Vianna</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bonan</surname><given-names>C.D.</given-names></name></person-group><article-title>Y-Maze Memory Task in Zebrafish (<italic toggle="yes">Danio Rerio</italic>): The Role of Glutamatergic and Cholinergic Systems on the Acquisition and Consolidation Periods</article-title><source>Neurobiol. Learn. Mem.</source><year>2012</year><volume>98</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2012.09.008</pub-id><pub-id pub-id-type="pmid">23044456</pub-id></element-citation></ref><ref id="B81-molecules-30-02858"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanello</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Ziani</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Mezzomo</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Rosemberg</surname><given-names>D.B.</given-names></name></person-group><article-title>Exploring Object Discrimination in Zebrafish: Behavioral Performance and Scopolamine-Induced Cognitive Deficits at Different Retention Intervals</article-title><source>Zebrafish</source><year>2019</year><volume>16</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1089/zeb.2018.1703</pub-id><pub-id pub-id-type="pmid">31145046</pub-id></element-citation></ref><ref id="B82-molecules-30-02858"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellman</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Andres</surname><given-names>V.</given-names></name><name name-style="western"><surname>Feather-Stone</surname><given-names>R.M.</given-names></name></person-group><article-title>A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity</article-title><source>Biochem. Pharmacol.</source><year>1961</year><volume>7</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(61)90145-9</pub-id><pub-id pub-id-type="pmid">13726518</pub-id></element-citation></ref><ref id="B83-molecules-30-02858"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winterbourn</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Brian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrell</surname><given-names>R.W.</given-names></name></person-group><article-title>The Estimation of Red Cell Superoxide Dismutase Activity</article-title><source>J. Lab. Clin. Med.</source><year>1975</year><volume>85</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">803541</pub-id></element-citation></ref><ref id="B84-molecules-30-02858"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>A.K.</given-names></name></person-group><article-title>Colorimetric Assay of Catalase</article-title><source>Anal. Biochem.</source><year>1972</year><volume>47</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(72)90132-7</pub-id><pub-id pub-id-type="pmid">4556490</pub-id></element-citation></ref><ref id="B85-molecules-30-02858"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuzawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tokumura</surname><given-names>A.</given-names></name></person-group><article-title>Glutathione Peroxidase Activity in Tissues of Vitamin E-Deficient Mice</article-title><source>J. Nutr. Sci. Vitaminol.</source><year>1976</year><volume>22</volume><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.3177/jnsv.22.405</pub-id><pub-id pub-id-type="pmid">1011051</pub-id></element-citation></ref><ref id="B86-molecules-30-02858"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salbitani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vona</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bottone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petriccione</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carfagna</surname><given-names>S.</given-names></name></person-group><article-title>Sulfur Deprivation Results in Oxidative Perturbation in Chlorella Sorokiniana (211/8k)</article-title><source>Plant Cell Physiol.</source><year>2015</year><volume>56</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1093/pcp/pcv015</pub-id><pub-id pub-id-type="pmid">25647328</pub-id></element-citation></ref><ref id="B87-molecules-30-02858"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohkawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohishi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yagi</surname><given-names>K.</given-names></name></person-group><article-title>Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction</article-title><source>Anal. Biochem.</source><year>1979</year><volume>95</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(79)90738-3</pub-id><pub-id pub-id-type="pmid">36810</pub-id></element-citation></ref><ref id="B88-molecules-30-02858"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Moerman</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stadtman</surname><given-names>E.R.</given-names></name></person-group><article-title>Age-Related Changes in Oxidized Proteins</article-title><source>J. Biol. Chem.</source><year>1987</year><volume>262</volume><fpage>5488</fpage><lpage>5491</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)45598-6</pub-id><pub-id pub-id-type="pmid">3571220</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="molecules-30-02858-f001" orientation="portrait"><label>Figure 1</label><caption><p>Effects of FVEO treatment (25, 150, and 300 &#956;L/L) on scopolamine (SCOP, 100 &#181;M)-exposed zebrafish in the novel tank test (NTT). Galantamine (GAL, 1 mg/L) was used as a positive control. (<bold>A</bold>) Schematic representation of zebrafish swimming patterns in the NTT; (<bold>B</bold>) number of entries into the top zone; (<bold>C</bold>) time spent in the top zone (s); (<bold>D</bold>) latency to first entry into the top zone (s); (<bold>E</bold>) distance traveled in the top zone (m); (<bold>F</bold>) freezing duration (s); (<bold>G</bold>) swimming velocity (m/s). Data are presented as mean &#177; S.E.M. (n = 10). Statistical analysis was performed using Tukey&#8217;s post hoc test: * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.001, *** <italic toggle="yes">p</italic> &lt; 0.0001, and **** <italic toggle="yes">p</italic> &lt; 0.00001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g001.jpg"/></fig><fig position="float" id="molecules-30-02858-f002" orientation="portrait"><label>Figure 2</label><caption><p>Effects of FVEO treatment (25, 150, and 300 &#181;L/L) on scopolamine (SCOP, 100 &#181;M)-induced cognitive impairment in zebrafish subjected to the Y-maze test. Galantamine (GAL, 1 mg/L) was used as a positive control. For Y-maze test: A&#8212;start arm; B&#8212;other arm and C&#8212;novel arm. (<bold>A</bold>) Representative locomotor trajectories during the second session of the Y-maze test; (<bold>B</bold>) distance traveled (m); (<bold>C</bold>) spontaneous alternation (%); (<bold>D</bold>) turn angle (&#176;); (<bold>E</bold>) time spent in the novel arm (s). Data are presented as mean &#177; S.E.M. (n = 10). Statistical analysis was performed using Tukey&#8217;s post hoc test: * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.001, and *** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g002.jpg"/></fig><fig position="float" id="molecules-30-02858-f003" orientation="portrait"><label>Figure 3</label><caption><p>Effects of FVEO treatment (25, 150, and 300 &#181;L/L) on recognition memory in scopolamine (SCOP, 100 &#181;M)-treated zebrafish in the novel object recognition (NOR) test. Galantamine (GAL, 1 mg/L) was used as a positive control. (<bold>A</bold>) Representative locomotor trajectories during the NOR test session. The familiar object zone is indicated by &#8220;F&#8221; and the novel object zone by &#8220;N&#8221;; (<bold>B</bold>) percentage preference for the novel object. Data are presented as mean &#177; S.E.M. (n = 10). Statistical analysis was performed using Tukey&#8217;s post hoc test: *** <italic toggle="yes">p</italic> &lt; 0.0001, and **** <italic toggle="yes">p</italic> &lt; 0.00001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g003.jpg"/></fig><fig position="float" id="molecules-30-02858-f004" orientation="portrait"><label>Figure 4</label><caption><p>Effects of FVEO treatment (25, 150, and 300 &#181;L/L) on acetylcholinesterase (AChE) specific activity in scopolamine (SCOP, 100 &#181;M)-treated zebrafish. Galantamine (GAL, 1 mg/L) was used as a positive control. Data are expressed as mean &#177; S.E.M. (n = 10). Statistical significance was determined using Tukey&#8217;s post hoc test: * <italic toggle="yes">p</italic> &lt; 0.05, *** <italic toggle="yes">p</italic> &lt; 0.0001, and **** <italic toggle="yes">p</italic> &lt; 0.00001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g004.jpg"/></fig><fig position="float" id="molecules-30-02858-f005" orientation="portrait"><label>Figure 5</label><caption><p>Effects of FVEO treatment (25, 150, and 300 &#181;L/L) on oxidative stress markers in scopolamine (SCOP, 100 &#181;M)-treated zebrafish. (<bold>A</bold>) Superoxide dismutase (SOD) activity; (<bold>B</bold>) catalase (CAT) activity; (<bold>C</bold>) glutathione peroxidase (GPX) activity; (<bold>D</bold>) reduced glutathione (GSH) levels; (<bold>E</bold>) protein carbonyl content; (<bold>F</bold>) malondialdehyde (MDA) levels. Galantamine (GAL, 1 mg/L) was used as a positive control. Data are expressed as mean &#177; S.E.M. (n = 10). Statistical significance was determined using Tukey&#8217;s post hoc test: * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.001, and *** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g005.jpg"/></fig><fig position="float" id="molecules-30-02858-f006" orientation="portrait"><label>Figure 6</label><caption><p>Pearson correlation analyses of behavioral and biochemical parameters in zebrafish. (<bold>A</bold>) Time spent in the top zone (NTT) vs. MDA levels (n = 10, r = &#8211;0.6683, <italic toggle="yes">p</italic> &lt; 0.0001); (<bold>B</bold>) time spent in the novel arm (Y-maze) vs. MDA levels (n = 10, r = &#8211;0.5218, <italic toggle="yes">p</italic> &lt; 0.01); (<bold>C</bold>) preference for the novel object (NOR test) vs. MDA levels (n = 10, r = &#8211;0.7628, <italic toggle="yes">p</italic> &lt; 0.0001); (<bold>D</bold>) AChE activity vs. MDA levels (n = 10, r = 0.6152, <italic toggle="yes">p</italic> &lt; 0.001); (<bold>E</bold>) SOD activity vs. MDA levels (n = 10, r = &#8211;0.6312, <italic toggle="yes">p</italic> &lt; 0.001); (<bold>F</bold>) carbonylated protein levels vs. MDA levels (n = 10, r = 0.6844, <italic toggle="yes">p</italic> &lt; 0.0001). Experimental groups include: (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i001.jpg"/>) Control, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i002.jpg"/>) Galantamine (GAL, 1 mg/L), (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i003.jpg"/>) FVEO 25 &#181;L/L, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i004.jpg"/>) FVEO 150 &#181;L/L, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i005.jpg"/>) FVEO 300 &#181;L/L, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i006.jpg"/>) Scopolamine (SCOP, 100 &#181;M), (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i007.jpg"/>) SCOP + GAL, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i008.jpg"/>) SCOP + FVEO 25 &#181;L/L, (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i009.jpg"/>) SCOP + FVEO 150 &#181;L/L, and (<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-02858-i010.jpg"/>) SCOP + FVEO 300 &#181;L/L.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g006.jpg"/></fig><fig position="float" id="molecules-30-02858-f007" orientation="portrait"><label>Figure 7</label><caption><p>Chemical structures of scopolamine (SCOP), galantamine (GAL), and the main constituents of <italic toggle="yes">Foeniculum vulgare</italic> essential oil (FVEO): <italic toggle="yes">&#946;</italic>-pinene, <italic toggle="yes">trans</italic>-sabinene hydrate, camphor, (+)-carvone, and <italic toggle="yes">trans</italic>-anethole.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g007.jpg"/></fig><fig position="float" id="molecules-30-02858-f008" orientation="portrait"><label>Figure 8</label><caption><p>Schematic representation of experimental design. FVEO: <italic toggle="yes">Foeniculum vulgare</italic> Mill. essential oil; SCOP: scopolamine; GAL: galantamine; NTT: novel tank diving test; NOR: novel object recognition test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-02858-g008.jpg"/></fig><table-wrap position="float" id="molecules-30-02858-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-02858-t001_Table 1</object-id><label>Table 1</label><caption><p>Physicochemical properties of chemical compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Descriptor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SCOP</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GAL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-Anethole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Camphor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-Sabinene<break/>Hydrate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">(+)-Carvone</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">&#946;</italic>-Pinene</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Molecular weight</td><td align="center" valign="middle" rowspan="1" colspan="1">303.358</td><td align="center" valign="middle" rowspan="1" colspan="1">287.359</td><td align="center" valign="middle" rowspan="1" colspan="1">148.20</td><td align="center" valign="middle" rowspan="1" colspan="1">152.23</td><td align="center" valign="middle" rowspan="1" colspan="1">154.253</td><td align="center" valign="middle" rowspan="1" colspan="1">150.22</td><td align="center" valign="middle" rowspan="1" colspan="1">136.23</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No. heavy atoms</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No. aroma heavy atoms</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LogP</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9181</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8503</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7283</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4017</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1935</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4879</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9987</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fraction csp<sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rotatable bonds</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acceptors</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Donors</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Molar refractivity</td><td align="center" valign="middle" rowspan="1" colspan="1">83.48</td><td align="center" valign="middle" rowspan="1" colspan="1">84.05</td><td align="center" valign="middle" rowspan="1" colspan="1">47.83</td><td align="center" valign="middle" rowspan="1" colspan="1">45.64</td><td align="center" valign="middle" rowspan="1" colspan="1">46.90</td><td align="center" valign="middle" rowspan="1" colspan="1">47.32</td><td align="center" valign="middle" rowspan="1" colspan="1">45.22</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Surface area</td><td align="center" valign="middle" rowspan="1" colspan="1">129.371</td><td align="center" valign="middle" rowspan="1" colspan="1">124.520 </td><td align="center" valign="middle" rowspan="1" colspan="1">67.315</td><td align="center" valign="middle" rowspan="1" colspan="1">68.174</td><td align="center" valign="middle" rowspan="1" colspan="1">68.806</td><td align="center" valign="middle" rowspan="1" colspan="1">67.800</td><td align="center" valign="middle" rowspan="1" colspan="1">63.322</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TPSA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.30 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.93 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.23 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.07 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.23 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.07 &#197;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 &#197;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-02858-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-02858-t002_Table 2</object-id><label>Table 2</label><caption><p>Prediction of intestinal absorption, P-glycoprotein substrate, P-glycoprotein I/II inhibitor, VDss, blood&#8211;brain barrier (BBB) permeability, CNS permeability, CYP3A4 substrate, CYP1A2 inhibitor, total clearance, renal OCT2 substrate, AMES toxicity, max. tolerated dose (human), oral rat acute toxicity (LD<sub>50</sub>), oral rat chronic toxicity (LOAEL), hepatotoxicity and skin sensitization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Property</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound<break/>Model Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SCOP</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GAL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-Anethole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Camphor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-Sabinene Hydrate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">(+)-Carvone</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">&#946;</italic>-Pinene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unit</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal absorption (human) (low &lt; 30%, high &gt; 30%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.626</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.994</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.592</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.965</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.786</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.702</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.525</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (% Absorbed)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-glycoprotein substrate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-glycoprotein I/II inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Distribution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDss (human)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.583</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.343</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.331</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.351</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.685</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log L/kg)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fraction unbound (human)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.414</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.266</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.459</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.469</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (Fu)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BBB permeability<break/>(log BB &gt; 0.3 cross BB, log BB &lt; 0.1 do not coross BB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.043</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.081</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.529</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.612</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.663</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.588</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.818</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log BB)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS permeability<break/>(log PS &gt; &#8722;2, penetrate CNS, log PS &lt; &#8722;3 do not penetrate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;3.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.511</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1.659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.158</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.478</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1.857</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log PS)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Metabolism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP3A4 substrate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP1A2 inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Excretion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Clearance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.096</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.991</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.109</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log ml/min/kg)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max. tolerated dose (human)<break/>(low &lt; 0.447, high &gt; 0.477)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.319</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.423</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.824</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.473</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.637</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.775</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.371</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log mg/kg/day)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Rat Acute Toxicity (LD50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.728</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.798</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.653</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.703</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.673</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (mol/kg)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Rat Chronic Toxicity (LOAEL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.736</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.966</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.981</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.926</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.972</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Numeric (log mg/kg_bw/day)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatotoxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin Sensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categorical (Yes/No)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-02858-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-02858-t003_Table 3</object-id><label>Table 3</label><caption><p>Estimated pharmacokinetic parameters of drug-likeness and medicinal chemistry of the compounds analyzed in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug-Likeness</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SCOP</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GAL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-<break/>Anethole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Camphor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Trans</italic>-<break/>Sabinene<break/>Hydrate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">(+)-Carvone</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">&#946;</italic>-Pinene</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lipinski</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 0 violation</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes; 1 violation: MLOGP &gt; 4.15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ghose</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 1 violation: MW &lt; 160</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 1 violation: MW &lt; 160</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 1 violation: MW &lt; 160</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 1 violation: MW &lt; 160</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 1 violation: MW &lt; 160</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Veber</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Egan</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muegge</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 2 violations: MW &lt; 200, Heteroatoms &lt; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 2 violations: MW &lt; 200, Heteroatoms &lt; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 2 violations: MW &lt; 200, Heteroatoms &lt; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 2 violations: MW &lt; 200, Heteroatoms &lt; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">No; 2 violations: MW &lt; 200, Heteroatoms &lt; 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bioavailability Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-02858-t004" orientation="portrait"><object-id pub-id-type="pii">molecules-30-02858-t004_Table 4</object-id><label>Table 4</label><caption><p>Biological activity prediction of scopolamine, galantamine, and the major constituents of <italic toggle="yes">Foeniculum vulgare</italic> essential oil using PASS Online.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Drug-Likeness</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">SCOP</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GAL</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">Trans</italic>-Anethole</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Camphor</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">Trans</italic>-Sabinene<break/>Hydrate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">(+)-Carvone</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">&#946;</italic>-Pinene</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pi</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACh nicotinic antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.249</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.080</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.083</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.089</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.127</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.169</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.128</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.148</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACh neuromuscular blocking agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.351</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.171</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.376</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.154</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.594</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.674</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.483</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.085</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.729</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholinergic antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.713</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.360</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.097</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.122</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.153</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.131</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.396</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.736</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.410</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.086</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.336</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.146</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.464</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.056</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotrophic factor enhancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.113</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.252</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.176</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.102</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.176</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.102</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.252</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.155</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.202</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.066</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dementia treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.285</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.164</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.458</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.499</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.574</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.540</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.332</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.105</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.537</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antineurotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.334</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.214</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.241</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.215</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.485</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.495</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.113</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.252</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.104</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.289</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.664</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.051</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiinflammatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.338</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.130</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.115</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.252</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.839</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.473</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.611</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delirium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.900</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.612</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.327</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.169</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.134</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.622</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.280</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.202</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.376</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.143</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Behavioral disturbance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.861</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.605</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.452</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.101</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.530</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.074</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.566</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.825</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.477</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.090</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.328</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.198</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.644</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.487</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.384</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.450</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.091</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.353</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.167</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.462</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.085</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid peroxidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.521</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.369</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.439</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.242</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.465</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.070</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.059</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NADPH peroxidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.431</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.369</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.488</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.457</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.381</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.111</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.299</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.162</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.369</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.117</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Pa</italic> (Active probability), <italic toggle="yes">Pi</italic> (Inactive probability).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>